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 1 
I SUMMARY 
 
Dendritic cells (DCs) play a pivotal role in the induction of antigen-specific immune 
responses. One important function required to achieve this role is the capacity to present 
extracellular antigen on MHC class I to CD8+ T cells (cross-presentation). We could 
previously show that the small Rho-GTPase Rac1 controls this function in spleen CD8+ 
DCs (Kerksiek et al., 2005). However, different DC subsets that have different functions 
could require the same Rho-GTPase for different processes. For this reason, we compared 
the role of Rac1 in different DCs. Furthermore, the model used in the mentioned study was 
based on the expression of a dominant negative (DN) variant of Rac1 (Rac1N17), which 
may not be completely specific for Rac1, as it may inhibit pathways controlled by similar 
Rho-GTPases. Therefore, we engineered mice with DC-specific knockouts (KO) of Rac1, 
Cdc42 and RhoA to investigate their individual roles in DCs. 
We found that Rac1 is neither required for uptake nor cross-presentation in 
Langerhans cells (LCs). Instead, Rac1 is required for the homeostasis and the migration of 
LCs. The comparison of Rac1N17 and Rac1-KO mice pointed out the unspecificity of DN 
proteins. Indeed, Rac1-KO mice have less LCs in the epidermis and no cross-presentation 
defect, unlike the Rac1N17 mice. The analysis of Rac1-, Cdc42- and RhoA-KO spleen DCs 
revealed a requirement of Rac1 and RhoA for CD8+ DC homeostasis, a reduced T cell 
priming capacity in Cdc42- and RhoA-KO mice as well as a decreased phagocytosis in all 
KO mice. To investigate the role of LCs in skin immune responses, we generated bone 
marrow chimeras. We show a role of LCs in the CD8+ T cell response but not in the CD4+ T 
cell priming. 
In this study, we showed that a DN form of Rac1 was not inhibiting only Rac1 
specific pathways. We could demonstrate that the Rho-GTPases regulate various functions 
in different DCs. Finally we get evidence that LCs contribute to CD8+ T cell response to 
particulate skin antigen. 
  
 2 
II ZUSAMMENFASSUNG 
 
Dendritische Zellen (DCs) spielen bei der Induktion von antigenspezifischen 
Immunantworten eine zentrale Rolle. Dafür müssen sie extrazelluläre Antigene aufnehmen 
und diese im Kontext von MHC Klasse I präsentieren (Kreuzpräsentation). Unsere Gruppe 
hat gezeigt, dass diese Funktion von der kleinen Rho-GTPase Rac1 gesteuert wird 
(Kerksiek et al., 2005). Es ist jedoch auch möglich, dass unterschiedliche Subtypen von 
DCs - wie z. B. Langerhans-Zellen (LCs) - die Rho-GTPase für verschiedene Vorgänge 
benötigen. Deswegen haben wir die Rolle von Rac1 für Milz-DCs und LCs verglichen. In 
früheren Arbeiten wurde eine dominant-negative (DN) Form von Rac1 (Rac1N17) 
verwendet. Diese Form könnte jedoch Prozesse ähnlicher Rho-GTPasen hemmen und wäre 
somit nicht spezifisch für Rac1. Aus diesem Grund haben wir Mausstämme mit jeweils 
einem für DCs spezifischen Knockout (KO) - Rac1, Cdc42 oder RhoA - generiert. 
Wir konnten zeigen, dass Rac1 nicht für die Antigenaufnahme oder für die 
Kreuzpräsentation in LCs gebraucht wird, aber für Homöostase und Wanderung der LCs 
nötig ist. Der Vergleich von Rac1N17 und Rac1-KO Mäusen konnte demonstrieren, dass 
das DN Modell nicht Rac1-spezifisch ist. Rac1-KO-Mäuse haben weniger LCs in der 
Epidermis und keinen Kreuzpräsentation-Defekt im Gegensatz zu den Rac1N17-Mäusen. 
Mit der Auswertung von Rac1-, Cdc42- und RhoA-KO-Milz-DCs, konnten wir feststellen, 
dass Rac1 und RhoA für die Homöostase von CD8+ Milz-DCs notwendig sind, dass die T-
Zell-Antwort niedriger in Cdc42- und RhoA-Mäusen ist und dass Phagozytose abhängig 
von allen drei Rho-GTPasen ist. Um die Rolle von LCs bei der Immunantwort auf 
Hautantigene zu untersuchen, haben wir Knochenmarkschimären mit Rac1N17-LC und 
WT-DCs (und umgekehrt) generiert. Dabei konnten wir beobachten, dass LCs für die CD8+ 
T-Zell-Antwort wichtig sind, aber dass sie keine Rolle bei der CD4+ T-Zell-Antwort 
spielen. 
In diesem Projekt haben wir somit den Nachweis erbracht, dass das dominant-
negative Modell nicht spezifisch für Rac1 ist, dass die Rho-GTPasen unterschiedliche 
Funktionen in verschiedenen DC Subtypen regulieren und dass LCs zu der CD8+ T-Zell-
Antwort auf Hautantigene beitragen. 
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III INTRODUCTION 
III.1 IMMUNE SYSTEM 
 
The immune system is composed of cells and mechanisms, which protect an 
organism against diseases. The first line of defence is the innate immune system. It is 
composed of physical barriers (skin, respiratory and gastric epithelia), chemical defences 
(enzymes in tears, gastric acid, mucus), physiological systems (e.g. complement system) 
and immune cells. These cells are mainly phagocytes and natural killer cells. The immune 
response generated by the innate immune system is quick, robust yet short-term and non-
specific. 
Evolved organisms like vertebrates have in addition an adaptive immune system. It 
specifically recognizes pathogens, generates a specific immune response and develops 
memory against them. Depending on the microorganism, humoral immunity (production of 
specific antibodies by B cells) and/or cellular immunity (antigen-specific T cells) can be 
established. B cells recognize native antigen through their B cell receptor, whereas T cells 
recognize antigen via their T cell receptor (TCR) as a peptide bound to major 
histocompatibility complex (MHC) molecules on antigen presenting cells (APC). This is 
how the response is initiated. 
 
III.2 DENDRITIC CELLS 
 
Monocytes, macrophages and dendritic cells (DCs) are potent APCs. However, DCs 
are the most effective APCs involved in the establishment of an adaptive immune response. 
Since their first description in 1973 (Steinman and Cohn, 1973), knowledge about these 
cells keeps increasing. Because this study is performed on murine DCs, only mouse data 
and information about DCs will be presented. 
DCs are located throughout the body, in direct contact with tissues and antigens. 
They have phagocytic capacities, engulfing particles and soluble molecules at high velocity 
almost constantly. This phagocytosed extracellular material is then degraded into peptides 
inside specialized intracellular compartments.  
After sensing inflammatory signals through pattern recognition receptors (PRRs), 
DCs migrate from organs to the lymph nodes (LNs) draining the organs, or from spleen red 
pulp to spleen white pulp. On the way, they up-regulate several molecules necessary for 
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antigen presentation at their surface, such as MHC class I and class II (MHC-I and MHC-
II), costimulatory molecules such as CD80/CD86 and CD40, as well as they produce 
cytokines. 
Once in the T cell area of the neighboring lymphoid organ, DCs can present peptides 
of antigen they have engulfed on MHC-I and MHC-II (for CD8+ and CD4+ T cell 
recognition respectively). However, the maturation status of the DCs can determine whether 
the response will be either immunogenic or tolerogenic (Reis e Sousa, 2006; Villadangos 
and Schnorrer, 2007). 
 
III.2.1 DC subsets 
 
DCs are a heterogeneous group of cells that have been categorized in many different 
subsets. They have been classified depending on their precursor origin (classical DCs 
(cDCs) versus plasmacytoid DCs (pDCs)), their location (lymphoid versus non-lymphoid 
tissue DCs) and their migratory behaviour (resident versus migratory DCs). In 2010, 
Guilliams and colleagues have proposed a simplified classification based on both location 
and functional similarities (Guilliams et al., 2010). As shown in Figure 1, they distinguish 
Langerhans cells, pDCs, inflammatory monocyte-derived DCs and two types of cDCs 
(CD11b+ and CD8+ DCs). Further descriptions will focus on spleen and lymph node DCs 
for lymphoid tissues and on skin DCs for non-lymphoid tissues. 
 
 
Figure 1: DC subsets in mice.  
In non-lymphoid tissues, the same subsets as in lymphoid tissues are found, except for the CD8+ DCs that 
have some differences in surface markers. Adapted from (Guilliams et al., 2010). 
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III.2.1.1 Lymphoid tissue DCs 
 
The lymphoid tissues comprise spleen, lymph nodes, thymus and mucosa-associated 
lymphoid tissues. This study focuses on spleen and LNs, which contain pDCs and cDCs 
(Figure 1). Only cDCs will be investigated in more detail. 
The cDCs can be subdivided into CD8+ CD11b-, CD8- CD11b+ and CD8- CD11b- 
subsets. The CD8+ CD11b- subset can present endogenous antigen on MHC-I and 
exogenous antigen on MHC-II (Pooley et al., 2001). Moreover, this subset is highly 
specialized in the presentation of exogenous antigen on MHC-I (den Haan et al., 2000), a 
process called cross-presentation. The CD8- CD11b+ population is more potent at 
presenting exogenous antigen on MHC-II (Dudziak et al., 2007) than on MHC-I (Pooley et 
al., 2001). The CD8- CD11b- subset, also called merocytic DCs (Thacker and Janssen, 
2012), is poorly described.  
The lymph nodes also contain migratory DCs arriving from drained tissues. They 
are described in the next section.  
 
III.2.1.2 Non-lymphoid tissue DCs 
 
In non-lymphoid tissues, there are usually two cDC populations related to the spleen 
cDC subsets according to transcriptional (Robbins et al., 2008), developmental (Ginhoux et 
al., 2009) and functional data (Edelson et al., 2010). The spleen CD11b+ DCs are related to 
tissue CD11b+ DCs and spleen CD8+ DCs correspond to the tissue CD103+ DCs. The skin 
contains one additional subset that is the Langerhans cell (LC) subset.  
 
The skin is composed of the superficial layer called epidermis and of the deeper 
dermis. The epidermis contains LCs whereas the dermis contains LCs leaving the 
epidermis, the classical CD11b+ DCs and the Langerin+ CD103+ DCs (Figure 2).  
Langerin+ dermal DCs (dDCs) were recently identified as a subset distinct from LCs 
due to their radiosensitivity (Bursch et al., 2007; Ginhoux et al., 2007; Poulin et al., 2007), 
which helps to differentiate them from radioresistant LCs (Merad et al., 2002). Their 
development depends on the transcription factor BATF3 (Edelson et al., 2010) and on the 
cytokine Flt3L (Ginhoux et al., 2009) but not on TGF-β (Kel et al., 2010) or M-CSF 
(Ginhoux et al., 2009). Langerin+ dDCs were identified as being responsible for most of the 
functions attributed so far to LCs (Bursch et al., 2007; Henri et al., 2010). They take part in 
contact hypersensitivity (CHS) reaction to topically applied haptens (Bursch et al., 2007; 
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Noordegraaf et al., 2010), induce CD8+ T cell response to leishmaniasis (Brewig et al., 
2009) and to herpes infection (Bedoui et al., 2009). Skin-derived antigens are cross-
presented by Langerin+ dDCs (Bedoui et al., 2009; Henri et al., 2010), but CD4+ T cell 
activation seems to be dependent on another cell type (Bedoui et al., 2009; Brewig et al., 
2009).  
 
 
Figure 2: DC subset markers.  
From (Kaplan, 2010). 
 
Langerhans cells were discovered in 1868 (Langerhans, 1868) and they are 
characterized by the expression of Langerin, which induces the formation of Birbeck 
granules, tennis racket-shaped organelles visible by electron microscopy (Birbeck et al., 
1961). These granules are found exclusively in LCs and not in Langerin+ dDCs. LCs are 
also positive for Epcam and negative for CD103 and CD11b (Figure 2). 
LCs precursors arrive in the skin before birth and develop lifelong in the epidermis 
(Chorro et al., 2009). LCs are maintained at the steady state by self-renewal (Merad et al., 
2002) thanks to an autocrine loop of TGF-β (Kaplan et al., 2007). M-CSF (Ginhoux et al., 
2006) and IL-34 (Wang et al., 2012) but not Flt3L (Onai et al., 2007) are required for LCs 
development. The estimated half-life of LCs is about 53 to 78 days (Vishwanath et al., 
2006). During inflammation, as LCs migrate out of the epidermis, they are replaced by 
blood-born monocyte-derived DCs that acquire LC markers (Nagao et al., 2012; Sere et al., 
2012).  
Although LCs are able to take up antigens and to prime naïve T cells (Schuler and 
Steinman, 1985; Holcmann et al., 2009), their function in immunity is not very clear. 
Indeed, until 2007 there was no distinction between Langerin+ dDC and LCs (Bursch et al., 
2007). LCs are not involved in either cross-presentation or graft versus host disease 
(GVHD) (Henri et al., 2010; Li et al., 2011). IL-17 producing T cells control fungal 
infection of the skin and LCs were recently shown to control this response (Igyarto et al., 
2011; Haley et al., 2012). They can also promote T helper cell type 2 (TH2) responses (Ding 
et al., 2008; Nagao et al., 2009). A role of LCs in tolerance induction and maintenance 
begins to emerge (Romani et al., 2012). Indeed, LCs negatively regulate the responses to 
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leishmaniasis (Kautz-Neu et al., 2011), skin graft (Obhrai et al., 2008), vaginal mucosa 
response (Hervouet et al., 2010), subcutaneous immunization (Shklovskaya et al., 2011) and 
self antigen (Holcmann et al., 2009; Seneschal et al., 2012). Whether LCs are required in 
CHS reactions is still a matter of debate (Kaplan, 2010). 
 
III.2.2 DC migration 
III.2.2.1 From the epidermis into the dermis 
 
LCs are further away from lymph vessels than dDCs. They first have to leave the 
epidermis to reach the dermis. Keratinocytes are the main cells composing the epidermis. 
They are known to produce pro- and anti-inflammatory cytokines (Ansel et al., 1990). 
Notably, the production of IL1-α and TNF-α activates LCs that in turn produce IL1-β 
((Heufler et al., 1992), Figure 3 and Figure 4.1). Then LCs detach from keratinocytes, 
become responsive to chemokines that induce migration to skin draining LNs (sdLNs), 
unresponsive to skin-homing chemokines and they acquire the machinery to cross the 
dermal-epidermal basement membrane (DEBM) (Cumberbatch et al., 2000; Villablanca and 
Mora, 2008). 
 
 
Figure 3: Signals and molecules required for LCs to exit the epidermis.  
Adapted from (Wang et al., 1999). 
 
To tear off surrounding keratinocytes, LCs down-regulate E-cadherin (Figure 4.2, 
(Schwarzenberger and Udey, 1996)). In order to adhere to matrix components, CD44 is up-
regulated (Weiss et al., 1997).  
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The DEBM is composed of lamimins and nidogen in the upper regions, type IV 
collagen and heparin sulphate proteoglycan in the lamina densa, and type VII collagen in 
the sub-basal lamina densa (Burgeson and Christiano, 1997; Behrens et al., 2012). 
Therefore, the expression of α6- and β1-integrins that bind laminins is up-regulated on LCs 
(Price et al., 1997), as well as the production of MMP-9 and MMP-2 that degrade type IV 
collagen (Figure 3 and Figure 4.3, (Ratzinger et al., 2002)). However, DEBM contains pre-
existing pores where LCs can go through (Oakford et al., 2011), if they distort enough their 
cytoskeleton and nucleus. 
Expression of CCR1 and CCR5, which control DC retention in the skin (Sallusto et 
al., 1998), is down-regulated whereas expression of CXCR4, which induces exit of the 
epidermis (Ouwehand et al., 2008), and expression of CCR7, which promotes migration to 
the sdLN, are up-regulated (Forster et al., 1999; Villablanca and Mora, 2008) (Figure 3). 
 
III.2.2.2 From the dermis into skin draining lymph nodes 
 
Once in the dermis, LCs and dDCs follow the same way and use the same molecular 
machinery. There is a continuous flow of DCs leaving the dermis to enter the lymph vessels 
and to migrate to the sdLN. Signals involved in DC emigration at the steady state are poorly 
understood, because of the difficulty of setting up a migration assay without inducing 
inflammation (Alvarez et al., 2008). 
Sensing inflammatory signals induce DCs to mature. The maturation process is 
characterized by increased motility, rearrangement of chemokine receptors and up-
regulation of the antigen presentation machinery (Granucci et al., 1999). Upon 
inflammation, similar to what happens for LCs, keratinocyte-produced cytokines promote 
dDC migration (Figure 4.1, (Mauviel et al., 1991; Cumberbatch et al., 1997)) and dDCs 
secrete metalloproteinases ((Ratzinger et al., 2002; Yen et al., 2008), Figure 4.3). 
The dDCs switch their chemokine receptor repertoire to one that is responding to 
LN-homing chemokines (Sallusto et al., 1998). The most characterized are the chemokines 
CCL19 and CCL21 and their receptor CCR7 (Figure 4.4 and Figure 4.5; (Schumann et al., 
2010)). CXCL12 and CCL17 being sensed by CXCR4 and CCR4 respectively were also 
shown to be important for DC migration (Kabashima et al., 2007; Stutte et al., 2010). 
Additionally, even if its precise mechanism is not known, S1P receptor is also required 
(Maeda et al., 2007; Ocana-Morgner et al., 2011). 
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Figure 4: DC mobilization in the skin.  
From (Alvarez et al., 2008). 
 
Finally DCs use integrins such as VLA-4 and LFA-1 to bind to endothelial cells 
((Joachim et al., 2008; Rouzaut et al., 2010), Figure 4.4) and to enter lymphatics, even if 
preformed pores exist to facilitate DC entry (Pflicke and Sixt, 2009). The travel from 
peripheral lymphatics to sdLNs is dependent on the CCL21 gradient (Tal et al., 2011).  
Of note, the distinct skin DC subsets arrive in sdLN with different kinetics. Indeed, 
dDCs arrive in sdLN as early as one day after immunization and peak after two days. On 
the other hand, LCs peak 4 days after immunization (Kissenpfennig et al., 2005). 
 
 
III.2.3 Induction of T cell response 
 
As already described before, DCs mature when they sense inflammation signals 
through PRRs (Kawai and Akira, 2009). This process leads to a down-regulation of antigen 
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uptake, increased antigen processing and peptide loading of MHC molecules, stabilization 
of MHC molecules at the plasma membrane, up-regulation of co-stimulatory molecules and 
expression of adhesion molecules and chemokine receptors required for migration to 
lymphoid organs (Reis e Sousa, 2006).  
Once in the lymphoid organ draining the tissue where the antigen was captured, DCs 
begin to sample T cells, until they encounter a T cell with a specific TCR recognizing the 
antigen they are presenting. CD4+ T cells recognize peptides presented on MHC-II whereas 
CD8+ T cells react to peptides on MHC-I (“signal 1”). Once CD4+ T cells have recognized 
the MHC-peptide complex, they arrest on the presenting APC. Here they receive “signal 2”, 
which consists in costimulatory signals provided by the binding of CD28 to CD80 or CD86 
and of CD40L to CD40. Then, depending on the DC subset and the inflammatory signals 
sensed at the site of antigen uptake, CD4+ T cells receive the “signal 3”. This is a 
combination of cytokines that determine the fate of the T cell (Figure 5) (Reis e Sousa, 
2006; Hirahara et al., 2011).  
For instance, IL-12 secretion will promote TH1 cell differentiation. These T cells 
produce IFNγ and provide help to CD8+ T cells, (Oestreich and Weinmann, 2012). 
Production of a Notch ligand by DCs will lead to the differentiation into TH2 cells, which 
secrete IL-4, IL-5 and IL-13 and which recruit eosinophils and B cells (Okoye and Wilson, 
2011). The production of IL-6, IL-23 and TGF-β by DCs will induce the development of 
TH17 cells. They are involved in protection against fungi and neutrophil recruitment, and 
they produce IL-17A, IL-17F and IL-22 (Bi and Yang, 2012). However, when DCs are not 
fully mature, e.g. at the steady state or in tumor environment, they produce TGF-β and 
IL10, promoting regulatory T cell differentiation to maintain tolerance against self-antigen 
(Luckashenak et al., 2008; Josefowicz et al., 2012).  
The CD8+ T cells need to be more tightly controlled to not over-react and cause 
auto-immunity. Indeed, after TCR engagement, they need to receive help from CD4+ T cells 
recognizing the same antigen, which will induce further CD8+ T cell differentiation into 
cytotoxic T lymphocyte (CTL) (Williams and Bevan, 2007; Zhang et al., 2009).  
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Figure 5: DC effector functions 
Depending on the maturation state and the subset of the DC presenting the antigen, T cells will differentiate 
into different kind of T helper cells, cytotoxic T lymphocytes (CTL) or die. (Reis e Sousa, 2006). 
 
III.3 SMALL Rho-GTPases 
 
Small Rho-GTPases play a role in almost all actin-dependent processes (Jaffe and 
Hall, 2005; Heasman and Ridley, 2008). The sequences and functions of these proteins are 
well conserved in eukaryotes. They were first discovered in the marine gastropod genus 
Aplysia (Madaule and Axel, 1985) and because of their similarities with the Ras protein 
family, they were named Ras homolog proteins (i.e. Rho proteins). According to their 
sequence similarities, the small Rho-GTPase family is composed of 20 members subdivided 
into 8 subfamilies (van Helden and Hordijk, 2011). I will focus on three members of this 
family Rac1, Cdc42 and RhoA that are subject of this study. 
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III.3.1 Turn over 
 
About 90 to 95 % of the small Rho-GTPases are confined in the cytosol by Rho-
specific guanine nucleotide dissociation inhibitors (GDIs). At the C-terminal part of Rho-
GTPases, there is a highly hydrophobic isoprenoid moiety, which impairs the proper folding 
of Rho-GTPases but which is necessary for their subcellular localization (Figure 6.a, (Cox 
and Der, 1992)). Therefore, GDIs stabilize the cytoplasmic pool of Rho-GTPases (Figure 
6.b, (Boulter et al., 2010)). GDIs are present in limited amounts compared to newly 
synthetized Rho-GTPases. Therefore, Rho-GTPases compete for the binding of GDIs 
(Figure 6.d). The overexpression of one Rho-GTPase leads to displacement of the 
endogenous Rho-GTPase pool from GDIs and to their targeting to proteasomal degradation 
(Figure 6.c).  
 
 
Figure 6: Classical small Rho-GTPase cycle.  
From (Garcia-Mata et al., 2011). 
 
Extracellular signals can activate Rho-specific guanine nucleotide exchange factors 
(GEFs), which will associate with phosphoinositides and lipid rafts in membranes. This 
proximity promotes the release of Rho-GTPase from GDIs, its association to membranes 
and its subsequent activation by GEFs (Figure 6.f, (Robbe et al., 2003; Ugolev et al., 
2008)). Interactions with specific proteins and GDI phosphorylation can also release the 
Rho-GTPase (Figure 6.e, (Garcia-Mata et al., 2011)). GEFs catalyse the exchange of the 
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GDP molecule bound to the Rho-GTPase for a GTP molecule leading to Rho-GTPase 
activity. This activity can be turned off by the extraction of the Rho-GTPase from the 
membrane by GDIs, by Rho-GTPase-post-translational modifications or by GTP hydrolysis. 
This hydrolysis is catalysed by Rho-specific GTPase-activating proteins (GAPs), which 
stimulate the slow hydrolysis property of the Rho-GTPase (Figure 6.f, (Ligeti et al., 2012)). 
GTP-bound Rho-GTPase can also be ubiquitylated for proteasomal degradation (Figure 
6.g, (Nethe and Hordijk, 2010)).  
The GEFs and GAPs can bind several Rho-GTPases (Figure 7), the identity of 
which depends on the activation pathway followed and on the cell type (Schiller, 2006; Bos 
et al., 2007; Buchsbaum, 2007). 
 
III.3.2 Function of the three main Rho-GTPases 
 
Rho-GTPase functions were studied in many different cell types (Pedersen and 
Brakebusch, 2012). In this chapter, the state of knowledge about the role of Rho-GTPases in 
DC functions will be discussed. Most of the studies were performed in vitro, by transfection 
of cells with wild type (WT), dominant negative (DN) or constitutively active (CA) variants 
of the targeted protein. The DN form is the result of a substitution mutation of a threonine 
for an asparagine at position 17 (Rac1 numbering). This mutation leads to a higher affinity 
for GEFs, so endogenous Rho-GTPases can neither bind to GEFs, nor be activated nor 
induce downstream effectors (Feig, 1999). The CA form has a substitution mutation of a 
glycine or a glutamine for a valine or a leucine at position 12 or 61, respectively.  They are 
unable to hydrolyse the GTP and remain bound to their effector molecules. The last past 
years, cell-specific knockouts (KOs) of Rho-GTPases were generated, based on the loxP 
system (Pedersen et al., 2012). These conditional KOs have become indispensable, as the 
complete KOs of Rac1, RhoA and Cdc42 are embryonically lethal (Sugihara et al., 1998; 
Chen et al., 2000; Pedersen and Brakebusch, 2012).  
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Cdc42 Rac1 RhoA References 
ECT2 ECT2 ECT2 (Tatsumoto et al., 1999) 
Negf = Ephexin1 Negf = Ephexin1 Negf = Ephexin1 (Shamah et al., 2001) 
VAV2 VAV2 VAV2 (Liu and Burridge, 2000) 
DEF6 = SWAP70-like DEF6 = SWAP70-like DEF6 = SWAP70-like (Mavrakis et al., 2004) 
DBL = Mcf2 DBL = Mcf2 DBL = Mcf2 (Hart et al., 1994; Yaku et al., 1994) 
DBS = Ost = Mcf2l DBS = Ost = Mcf2l DBS = Ost = Mcf2l (Horii et al., 1994) 
ARHGEF6 = alpha-Pix ARHGEF6 = alpha-Pix   (Zheng, 2001; Rossman et al., 2005; Schiller, 2006) 
Asef2 = Spata3 Asef2 = Spata3   (Kawasaki et al., 2007; Bristow et al., 2009) 
DOCK6 DOCK6   (Miyamoto et al., 2007) 
  VAV3 VAV3 (Movilla and Bustelo, 1999) 
  ARHGEF2 = GEF-H1 = Lfc 
ARHGEF2 = GEF-H1 
= Lfc 
(Ren et al., 1998; Glaven et 
al., 1999) 
  SWAP70 SWAP70 (Shinohara et al., 2002; Ocana-Morgner et al., 2009) 
  VAV1 VAV1 (Rossman et al., 2005; Spurrell et al., 2009) 
  Kalirin = Duo Kalirin = Duo (Penzes et al., 2001; Zheng, 2001) 
  SmgGDS = KAP3 = Kifap3 
SmgGDS = KAP3 = 
Kifap3 (Lanning et al., 2003) 
  ARHGEF18 = p114RhoGEF 
ARHGEF18 = 
p114RhoGEF (Zheng, 2001; Niu et al., 2003) 
ARHGEF4 = Asef (1) P-Rex1 = Setd6 (2) Lbc = Brx = Akap3 (3) 
(1) (Gotthardt and Ahmadian, 
2007), (2) (Welch et al., 2002; 
Balamatsias et al., 2011), (3) 
(Glaven et al., 1996) 
FGD4 = Frabin (1) P-Rex2 = Depdc2 (2) p190RhoGEF = Rgneg + Rasgrf1 (3) 
(1) (Ono et al., 2000), (2) 
(Donald et al., 2004; Joseph 
and Norris, 2005) (3) (Jaiswal 
et al., 2011; Miller et al., 2012) 
DOCK8 (1) Tiam1 (2) 
ARHGEF1 = 
p115RhoGEF = Lcs = 
Lbcl2 (3) 
(1) (Ruusala and Aspenstrom, 
2004), (2) (Habets et al., 1994; 
Rossman et al., 2005), (3) 
(Glaven et al., 1996; Mao et 
al., 1998; Jaiswal et al., 2011) 
FGD2 = Tcd2 = Tcs2 (1) Tiam2 = Stef (2) ARHGEF3 = XPLN (3) 
(1) (Huber et al., 2008), (2) 
(Zheng, 2001), (3) (Arthur et 
al., 2002) 
DOCK9 = Zizimin1 (1) DOCK2 (2) ARHGEF8 = Net1 (3) 
(1, 2) (Kulkarni et al., 2011), 
(3) (Alberts and Treisman, 
1998; Dubash et al., 2011) 
DOCK11 = Zizimin2 (1) DOCK1 = DOCK180 (2) 
ARHGEF12 = LARG 
(3) 
(1) (Lin et al., 2006), (2) 
(Brugnera et al., 2002), (3) 
(Taya et al., 2001; Jaiswal et 
al., 2011) 
ARHGEF9 = hPEM-2 (1) ELMO/CDE-12 = Elmod3dc1 (2) 
ARHGEF11 = 
KIAA0380 = PDZ-
RhoGEF (3) 
(1) (Zheng, 2001), (2) 
(Brugnera et al., 2002), (3) 
(Jaiswal et al., 2011) 
Ese1 = Itsn1 = 
Intersectin1 (1) TrioPH1 (2) TrioPH2 (3) 
(1) (Zheng, 2001), (2, 3) 
(Bellanger et al., 2003) 
FGD1 = ZFYVE3 (1) Sos1 (2)   
(1) (Zheng et al., 1996; 
Hayakawa et al., 2005), (2) 
(Das et al., 2000; Furuta et al., 
2002) 
  ARHGEF7 = beta-Pix = Pix = Cool (2)   (2) (Feng et al., 2002) 
Figure 7: Cdc42-, Rac1- and RhoA-GEF 
GEFs common to Cdc42, Rac1 and RhoA (blue); to Cdc42 and Rac1 (orange); to Rac1 and RhoA (green); 
GEFs specific for Cdc42, Rac1 or RhoA (white). 
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III.3.2.1 Rac1 
 
At the biochemical level (Jaffe and Hall, 2005), Rac1 interacts with effectors 
involved in actin-cytoskeleton reorganization. Therefore, disturbing Rac1 expression or 
activity leads to several phenotypes. 
Spleen Rac1-DN DCs have no migration defects, but Rac1 controls apoptotic cell 
phagocytosis (Kerksiek et al., 2005) and macropinocytosis (West et al., 2000) in DCs. Rac1 
also regulates the transport to plasma membrane of molecules required for immune 
response induction as well as cross-presentation in DCs (Benvenuti et al., 2004; Jaksits et 
al., 2004; Kerksiek et al., 2005; Shurin et al., 2005). 
In other cell types Rac1 was reported to be involved in the control of gene 
expression (Coso et al., 1995; Minden et al., 1995) as it contains a nuclear localization 
sequence (Lanning et al., 2003), in the control of the cell cycle (Olson et al., 1995) and in 
the production of reactive oxygen species (ROS) (Sarfstein et al., 2004; Wu et al., 2009). 
Whether this is also the case in DCs has to be investigated.  
 
III.3.2.2 Cdc42 
 
Cdc42 activates several effectors, some of which being common with Rac1, 
therefore leading to a phenotype similar to the one describe above.  
Cdc42 controls DC migration (Swetman et al., 2002; Lammermann et al., 2009; 
Luckashenak et al., 2013), adhesion (Shurin et al., 2005) and protrusion formation 
(Lammermann et al., 2009). Endocytosis (Shurin et al., 2005) but not pinocytosis (West et 
al., 2000) requires Cdc42 activity in DCs. Finally, Cdc42 regulates the reorganisation of the 
microtubule organisation center (MTOC) required for the formation of the immunological 
synapse (Pulecio et al., 2010) and it controls the transport to plasma membrane of 
molecules required for immune response induction (Jaksits et al., 2004). Antigen 
presentation is therefore dependant on Cdc42 (Shurin et al., 2005). 
Similar to Rac1, the role of Cdc42 in the control of gene expression (Coso et al., 
1995; Minden et al., 1995), of the cell cycle (Olson et al., 1995) and in ROS production was 
reported in other cell types but remains to be investigated in DCs. 
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III.3.2.3 RhoA 
 
RhoA activates different effectors than Rac1 and CDC42, which mainly control 
myosin phosphorylation and microtubule dynamic.  
In DCs, RhoA promotes the release of adhesion (Swetman et al., 2002) and the 
dissolution of podosomes (van Helden et al., 2008). At the organism level, depending on the 
type of migration, RhoA controls either positively or negatively DC migration (Quast et al., 
2009; Ocana-Morgner et al., 2011). RhoA seems to counteract the events controlled by 
Rac1 and Cdc42. For instance, receptor-mediated endocytosis in DCs is inhibited by RhoA 
activity (Leverrier and Ridley, 2001; Nakaya et al., 2006; Ocana-Morgner et al., 2011), but 
RhoA is not involved in pinocytosis (West et al., 2000). There are no data on the 
importance of RhoA in DCs for the initiation of immune responses. 
 
III.4 AIM OF THE PROJECT 
 
This project is composed of three distinct parts investigating the role of Rho-
GTPases in dendritic cell functions. 
The laboratory of Thomas Brocker has developed a mouse model where a dominant 
negative variant of Rac1 is expressed in CD11c+ cells (Rac1N17 mouse, (Kerksiek et al., 
2005; Neuenhahn et al., 2006; Luckashenak et al., 2008; Luckashenak et al., 2013)). It has 
been published that spleen DCs from these mice fail to take up soluble molecules, apoptotic 
cells and bacteria. These cells have a cross-presentation defect but a normal migration 
capacity. In the first part of this study, we were interested in the effects of Rac1N17-
expression in skin DCs and particularly in Langerhans cells. 
As explained in the previous pages (Figure 7, (Feig, 1999; Guilluy et al., 2011)), the 
utilisation of a dominant negative variant is not very specific. We compared dominant 
negative transgenic mice with DC-specific conditional Rac1-KO mice, to find out what the 
real functions of the Rho-GTPase Rac1 in skin DCs are. 
Finally, in the last part of this work, we investigated which protein functions were 
actually inhibited in Rac1N17 spleen DCs, by comparing them to spleen DCs deficient for 
Rac1, Cdc42 and RhoA. 
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IV MATERIALS AND METHODS 
IV.1 MATERIAL 
IV.1.1 Antibodies for flow cytometry 
 
Specificity (anti-mouse)  Conjugate  Clone  Supplier  
CD103 PE M290 BD Pharmingen 
 Biotin 2E7 eBioscience 
CD11c FITC HL3 BD Pharmingen 
 PE-Cy7 HL3 BD Pharmingen 
CD16/32 (FC-block) None 2.4G2 BD Pharmingen 
CD184 (CXCR4) AF-647 TG12/CXCR4 Biolegend 
CD195 (CCR5) AF-488 HM-CCR5 Biolegend 
CD197 (CCR7) APC 4B12 eBioscience 
CD207 (Langerin) AF-647 929F3.01 Dendritics 
CD324 (E-cadherin) AF-647 DECMA-1 eBioscience 
CD326 (Epcam) PerCP-Cy5.5 G8.8 Biolegend 
CD4 PE-Cy7 L3T4 eBioscience 
CD40 APC HM40-3 eBioscience 
CD45 APC-eF780 30-F11 eBioscience 
CD45.1 FITC A20 BD Pharmingen 
 APC A20 eBioscience 
CD45.2 APC 104 eBioscience 
CD49f (a6-integrin) AF-488 GoH3 Biolegend 
CD8 FITC 53-6.7 eBioscience 
 PerCP 53-6.7 BD Pharmingen 
 APC-Cy7 53-6.7 eBioscience 
CD80 Biotin 16-10A1 eBioscience 
CD86 Biotin GL1 BD Pharmingen 
CD90.1 PerCP OX-7 BD Pharmingen 
F4/80 PE BM8 eBioscience 
H-2Db FITC KH95 BD Pharmingen 
I-Ab FITC AF6-120.1 BD Pharmingen 
 PE AF6-120.1 BD Pharmingen 
 PE-Cy5 M5/114.15.2 eBioscience 
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 biotin AF6-120.1 BD Pharmingen 
IFNγ APC XMG1.2 eBioscience 
Streptavidin PerCP   BD Pharmingen 
  Pacific Blue   Invitrogen 
TFNα APC MP6-XT22 eBioscience 
Vα2-TCR PE B20.1 eBioscience 
Vβ5.1/5.2-TCR FITC MR9-4 BD Pharmingen 
 
IV.1.2 Antibodies for western blot 
 
Specificity  Host Dilution Time Solution Supplier 
β-Actin rabbit  1/1000 1h PBST Cell Signaling 
Rac1 mouse  1/500 1h30 PBST Cytoskeleton 
Mouse   1/2000 1h30 PBST + 1 % milk powder Jackson Lab 
Rabbit donkey  1/2500 1h30 PBST + 5 % milk powder Jackson Lab 
 
IV.1.3 Chemicals 
 
If not stated differently, chemicals were purchased from Merck (Darmstadt, 
Germany), Roth (Karlsruhe, Germany) or Sigma-Aldrich (St. Louis, MO, USA). All buffers 
and solutions were prepared using double distilled water. 
 
IV.1.4 Consumables 
 
Mesh filter 41 µm   Reichelt Chemietechnik, Heidelberg, Germany 
injection needles 26 G x 1/2  Terumo Medical Corporation, Tokyo, Japan 
disposable syringes (1 ml)  Braun, Melsungen, Germany  
tubes 1.5 ml und 2 ml    Eppendorf, Hamburg, Germany  
tubes 5 ml     SARSTEDT, Nümbrecht, Germany 
 
Other materials and plastic wares were purchased from BD, Nunc (Wiesbaden, 
Germany) and Greiner (Frickenhausen, Germany). 
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IV.1.5 Devices 
 
Analytic scale (Adventurer, Ohaus Corp., Pine Brooks, NJ, USA), automatic pipettors 
(Integra Biosciences, Baar, Switzerland), bench centrifuge (Centrifuge 5415 D, Eppendorf, 
Hamburg, Germany), cell counter (Coulter Counter Z2, Beckman Coulter, Krefeld, 
Germany), centrifuge (Rotixa RP, Hettich, Tuttlingen, Germany), chemical scale (Kern, 
Albstadt, Germany), flow cytometer (FACSCalibur, FACSCantoII, FACSAria BD), 
incubator (Hera cell, Heraeus Kendro Laboratory Products, Hanau, Germany), laminar 
airflow cabinet (Heraeus), magnetic stirrer (Ika Labortechnik, Staufen, Germany), PCR-
machine (Biometra, Goettingen, Germany), pH-meter (Inolab, Weilheim, Germany), 
pipettes (Greine, Frickenhausen, Germany), power supply (Amersham Pharmacia, 
Piscataway, NJ, USA), vacuum pump (KNF Neuberger, Munzingen, Germany), water bath 
(Grant Instruments Ltd., Barrington Cambridge, UK).  
 
All other devices are mentioned in the methods section. 
 
IV.1.6 Medium and buffers 
 
PBS (Phosphate buffered saline) 150 mM NaCl  
10 mM Na2HPO4  
2 mM KH2PO4  
pH 7.4 
or Dulbecco’s PBS without Ca2+/Mg2+ (Gibco, 
Invitrogen, Carlsbad, CA, USA) 
 
Culture medium RPMI 1640 (PAA, Pasching, Austria) 
10 % FCS (Gibco) 
0.05 mM (1%) βmercaptoethanol (PAN biotech 
GmbH) 
100 U/ml Penicillin (PAN biotech GmbH) 
100 µg/ml Streptomycin (PAN biotech GmbH) 
10 mM Hepes (Gibco) 
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MACS buffer PBS 
0.5 % FCS 
8 µM EDTA 
 
FACS buffer PBS 
2 % FCS 
0.01 % NaN3 
 
Anesthetic PBS 
2 % Rompun (Bayer) 
10 mg/ml Ketavet (Pfistzer) 
 
ACK buffer 1 L H2O 
8.29 g NH4Cl 
1 g KHCO3 
37.2 mg Na2EDTA 
pH 7.3 
 
50x TAE buffer 1 L H2O 
242 g Tris 
57.1 ml 100 % acetic acid 
100 ml 0.5 M EDTA 
pH 8.0 
 
Borate buffer H2O 
0,1 M boric acid 
pH 8.5 
 
Storage buffer PBS 
10 mg/ml BSA sterile filtrated 
0.1 % NaN3 
5 % glycerol 
pH 7.4 
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10X Gitocher buffer 670 mM Tris pH 8.8 
166 mM (NH4)2SO3 
65 mM MgCl2 
0.1 % Gelatin 
 
Digestion mix for genotyping H2O 
1X Gitocher buffer 
0.5 % Triton-X 
1 % βmercaptoethanol 
0.4 mg/ml Proteinase K 
 
Western blot solutions:  
Lysis buffer 50 mM Tris/HCl pH 8.8 
150 mM NaCl 
1 % NP40 
1/100 protease inhibitor cocktail 
1 mM PMSF 
 
Resolving gel 12% H2O 
30 % Acrylamid/Bisacrylamid-mix 
1.5 mM Tris/HCl pH 8.8 
1 % SDS 
1 % APS 
0.04 % TEMED 
 
Stacking gel 5% H2O 
30 % Acrylamid/Bisacrylamid-mix 
1 M Tris/HCl pH 6.8 
1 % SDS 
1 % APS 
0.1 % TEMED 
 
Running buffer 25 mM Tris Base 
192 mM Glycin  
0.1 % SDS 
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Blotting buffer 25 mM Tris-Base 
192 mM Glycin 
20 % Methanol 
0.002 % SDS 
 
PBST PBS 
0.05 % Tween-20 
 
Blocking buffer  PBST 
Milk powder 5 % 
 
Stripping buffer 62.5 mM Tris HCl pH 6.7 
2 % SDS, warm 15 min at 55°C 
100 mM βmercaptoethanol at the last moment in 
warm solution 
 
IV.1.7 Protein, peptide and oligonucleotides 
 
Ovalbumin (albumin from chicken egg, OVA, Grade VII) was purchased from 
Sigma-Aldrich (St. Louis, MO, USA). The peptide OVA257-264 SIINFEKL was purchased 
from PolyPeptide Group (Strasbourg, France). The following oligonucleotides were 
purchased from MWG-Biotech AG (Edersberg, Germany) 
 
For qPCR 
IL1-α 5´ GAGCGCTCACGAACAGTTG  Probe 52 
IL1-α 3´ TTGGTTAAATGACCTGCAACA  
IL1-β 5´ TCTTCTTTGGGTATTGCTTGG  Probe 78 
IL1-β 3´ TGTAATGAAAGACGGCACACC   
TNF-α 5´ GGTTGTCTTTGAGATCCATGC Probe 79 
TNF-α 3´ CTGTAGCCCACGTCGTAGC  
TGF-β 5´ CAGCAGCCGGTTACCAAG  Probe 72 
TGF-β 3´ TGGAGCAACATGTGGAACTC   
HPRT 5´ CCTGGTTCATCATCGCTAATC  Probe 95 
HPRT 3´ TCCTCCTCAGACCGCTTTT   
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For PCR: 
Rac1-flox 5´ GTCTTGAGTTACATCTCTGG 
Rac1-flox 3´ CTGACGCCAACAACTATGC 
Rac1N17 5´ AACCAATGCATTTCCTGGAG 
Rac1N17 3´ (Rac reverse) AGGGTACCACTTTGCTCGAA 
Rac left 5´ CTGATCAGTTACACAACCAATGC 
Cre 5´ GGACATGTTCAGGGATCGCCAGGCG 
Cre 3´ GCATAACCAGTGAAACAGCATTGCTG 
 
IV.1.8 Mice 
 
All mice were bred and maintained at the animal facility of the Institute for 
Immunology (LMU, Munich). 
 
IV.1.8.1 C57BL/6 and BALB/cJ 
 
The MHC-haplotype of C57BL/6 strain is H-2b. Mice from this strain express the 
congenic markers CD45.2 and CD90.2 on all leukocytes. A congenic strain expressing 
CD45.1 was also used. The MHC-haplotype of BALB/cJ strain is H-2d. 
 
IV.1.8.2 OT-I and OT-II 
 
CD8+ T cells from OT-I mice express a transgenic Vα2/Vβ5 TCR, which recognizes 
the ovalbumin peptide OVA257–264, in the context of MHC-I H2-Kb (Hogquist et al., 1994). 
These mice express the congenic marker CD90.1 on the C57BL/6 background. 
CD4+ T cells from OT-II mice express a transgenic Vα2/Vβ5 TCR, which 
recognizes the ovalbumin peptide OVA323-339 in the context of MHC-II I-Ab (Robertson et 
al., 2000). These mice express the congenic marker CD90.1 on the C57BL/6 background. 
 
IV.1.8.3 Rac1N17 mice 
 
Rac1N17 mice express the transgenic dominant negative form of the small Rho-
GTPase Rac1 in CD11c+ cells (abbreviated Rac1N17 mice (Kerksiek et al., 2005)).  
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These mice are on the C57BL/6 background. 
 
IV.1.8.4 Rac1-flox in CD11c-Cre and Langerin-Cre 
 
To generate mice with DCs deficient for the small Rho-GTPase Rac1 (Figure 8), 
Rac1fl/fl mice (Benninger et al., 2007) provided by Cord Brakebusch (University of 
Copenhagen, Copenhagen, Denmark) were crossed with either CD11c-Cre mice (Caton et 
al., 2007) provided by Boris Reizis (Columbia University, New York, NY, USA) or 
Langerin-Cre mice (Zahner et al., 2011) provided by Bjorn Clausen (Erasmus University 
Medical Center, Rotterdam, The Nederland). These mice are abbreviated CD11c-Rac1-/- 
and Lang-Rac1-/- mice respectively. These mice were backcrossed on the C57BL/6 
background. 
 
 
Figure 8: Generation of mice deleted of Rac1, Cdc42 and RhoA in DCs 
Adapted from (Caton et al., 2007) and from (Benninger et al., 2007). 
 
IV.1.8.5 Cdc42-flox in CD11c-Cre and RhoA-flox in CD11c-Cre 
 
To generate mice with DCs deficient for the small Rho-GTPases Cdc42 or RhoA 
(Figure 8), Cdc42fl/fl or RhoAfl/fl mice (Wu et al., 2006) provided by Cord Brakebusch 
(University of Copenhagen, Copenhagen, Denmark) were crossed with CD11c-Cre mice 
(Caton et al., 2007) provided by Boris Reizis (Columbia University, New York, NY, USA). 
These mice were abbreviated Cdc42-/- and RhoA-/- mice respectively. Nancy Luckashenak, 
Anna Wähe and Shuai Li provided genotyped mice. These mice are on the C57BL/6 
background. 
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IV.2 METHODS 
IV.2.1 Cellular and immunological methods 
IV.2.1.1 In vivo assays and immunization 
IV.2.1.1.a Adoptive transfer 
 
This method consists in the transfer of T cells from a donor mouse into a recipient 
mouse. T cells were isolated from spleens and lymph nodes of donor mice using magnetic 
CD8 or CD4 negative selection (MACS®, IV.2.1.2.b) and CFSE-labeled (IV.2.1.2.c). Cell 
purity was determined by flow cytometry (IV.2.1.2.e). Either 106 CD8+ T cells or 2x106 
CD4+ T cells were injected i.v. into syngenic recipients of the same sex. The congenic 
marker CD90.1 allows subsequent detection of transferred T cells in the recipient. 
 
IV.2.1.1.b Intradermal immunization 
 
Mice were anesthetized with intraperitoneal injection of 150 µl of the anesthetic 
(IV.1.6). They were shaved on the left flank and 5 µg of OVA-coated polystyrene beads 
(IV.2.2.6) were injected intradermally in a maximum volume of 30 µl. As an irritant, 15 µl 
acetone were added on the skin at the injection site. Proliferation of T cells was assessed 5 
days later. 
 
IV.2.1.1.c Uptake of apoptotic cells 
 
Splenic B cells were isolated from BALB/cJ mice using CD19 positive selection 
(MACS®, IV.2.1.2.b). Cells were labeled with 5 µM of CFSE (IV.2.1.2.c) and 107 cells 
were injected i.v. in the recipient mice. The MHC mismatch between the injected cells and 
the recipient mouse leads to opsonization of the foreign cells and their subsequent 
phagocytosis by recipient APCs. Uptake was investigated 14 hours later. 
 
 
IV.2.1.1.d FITC painting 
 
A 10 mg/ml solution (1 %) of FITC was prepared in a mix 1:1 of acetone and 
dibutylphthalate. Mice were anesthetized, shaved on the abdomen and painted with 200 µl 
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of the FITC solution (2 mg). Four days later, mice were sacrificed and inguinal and axillary 
lymph nodes were removed to assess the presence of FITC+ cells. 
 
IV.2.1.1.e Bone marrow chimeras 
 
The recipient mice (minimum 10 weeks old) were irradiated a first time with 550 rad 
from a 137-Cesium source (Model G.C. 40; Type B(4); Atomic Energy of Canada Limited,  
Ontario, Canada) and 48 hours later they were irradiated a second time with 550 rad. From 
the first irradiation until 6 weeks after reconstitution, recipient mice received water with 1.2 
g/l of Neomycin. Four hours after the second irradiation, recipient mice were reconstituted 
with intravenous injection of 107 cells from the desired bone marrow depleted of 
erythrocytes. Bone marrow cells from leg bones of the donor mice (minimum 8 weeks old) 
were prepared as described in IV.2.1.3.a and IV.2.1.3.b. Six weeks after reconstitution, 
antibiotic was stopped and chimerism in blood was analyzed on T and B cells. Experiments 
were performed between 8 and 10 weeks after reconstitution. When the mice were 
sacrificed, the ears were removed and skin DC chimerism was analyzed. 
 
IV.2.1.2 Ex vivo manipulations common to the different organs or cell 
types 
IV.2.1.2.a Determination of cell numbers 
 
Cell count and size are measured by the change of electrical resistance that a cell 
causes by passing through the hole of the electrode. For analysis, cell suspensions were 
diluted in a conductive solution (Isoton II, Beckman Coulter) and 2 drops of a lytic reagent 
(ZAP-OGLOBIN II, Beckman Coulter) were added to remove residual erythrocytes. 
 
IV.2.1.2.b Magnetic cell separation (MACS®) 
 
Magnetic cell sorting (MACS®, Miltenyi Biotec, Bergisch-Gladbach, Germany) is a 
technique that allows the isolation of different cell-subpopulations based on their expression 
of different antigens on the cell surface. This can be achieved by positive or negative 
selection. Targeted cells are bound to MACS® colloidal super-magnetic MicroBeads. 
Passing the cell suspension through a column, which is maintained in a magnetic field, 
separates the positive fraction from the negative one. For some positive selection 
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procedures, positive cells were passed through a second column to increase purity. 
MACS® separation was applied to purify spleen DCs (CD11c Microbeads, positive 
selection; CD8+ DCs isolation kit, negative and positive selections), B cells (CD19 Micro 
Beads, positive selection), CD8+ T and CD4+ T cells (CD8+ T cell Isolation Kit and CD4+ T 
cell Isolation Kit, negative selections) and epidermal LCs (Epidermal Langerhans Cells 
MicroBeads Kit, positive selection). The instructions of the manufacturer were followed for 
all the procedures. To isolate LCs from bone marrow derived LC (BMLC) cultures, we used 
anti-biotin beads in combination with I-Ab-biotin antibody (IV.1.1). 
 
IV.2.1.2.c CFSE labelling 
 
CFSE (carboxyfluorescein-diacetate-succinimidylester) staining is used to track cell 
divisions both in vitro and in vivo. CSFE binds to amino groups of intra- and extra-cellular 
proteins. When cleaved by intracellular esterases, CFSE becomes a fluorescent dye. After 
each cell division, the amount of dye is equally divided between the daughter cells and the 
intensity of the fluorescence is reduced about 50 %. The number of cell divisions can be 
identified by the number of times the fluorescence intensity is reduced by the half.  
The cells were resuspended in pre-warmed PBS with 0.03 % FCS (1 ml per 1 to 
50x106 cells) and CSFE was added at 5 µM or 0.5 µM for in vivo or in vitro experiments, 
respectively. The cells were incubated for 10 minutes at 37°C in a water bath and protected 
from light. The reaction was stopped by addition of an equal amount of pure FCS. The cells 
were washed twice with PBS and resuspended at the desired concentration in PBS or 
culture medium. 
 
IV.2.1.2.d Ex vivo antigen uptake 
 
Epidermal cell suspensions or MACS® purified CD8+ DCs were resuspended at 
5x105 cells per ml of culture medium (IV.1.6) with 5 µg/ml of OVA-AF647, 250 µg/ml of 
FITC-dextran or 500 µg/ml of luciferase-yellow (all from Molecular Probes) in 96 well-
plate (WP) with U-bottom. Cell suspensions were then incubated for 40 min at 37°C or 4°C. 
The cells were intensively washed to stop the reaction. During the staining procedure, plates 
were kept on ice until fixation to avoid any further uptake or processing of residual antigen. 
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IV.2.1.2.e FACS 
 
In flow cytometry, various cell characteristics such as size, granularity and marker 
expression can be detected. Cells are stained with fluorochrome-coupled antibodies against 
surface or intracellular antigens. In a fluid stream, cells pass a laser beam and several 
detectors. The resulting information is acquired and can be used to identify distinct cell 
populations within a heterogeneous mixture of cells.  
In a 96 WP, 100 µl of a single cell suspension (1 to 5x106 cells) were washed in 
FACS buffer (IV.1.6). Cells were incubated for 20 min in the dark at 4°C with 100 µl of 
antibody solution (IV.1.1) at the appropriate dilution; antibodies were titrated before use. 
The cells were then washed with FACS buffer to remove the excess of unbound antibodies. 
If biotinylated antibodies were used, a second staining step with fluorochrome-conjugated 
streptavidin followed. The CCR7 antibody requires an staining step at 37°C prior to the 
classical surface staining for the other markers at 4°C. 
Intracellular staining was performed according to the manufacturer’s protocol with 
the Cytofix/Cytoperm kit (BD Bioscience). To analyze cytokine production, 10x106 sdLN 
cells were restimulated 4 hours in 2 ml of culture medium (IV.1.6) plus 20 ng/ml of GM-
CSF, which was produced in our laboratory, and 2 µl of GolgiStop (BD Bioscience), which 
blocks protein secretion, with either 2 µg of SIINFEKL peptide or 40 ng/ml of PMA and 2 
µg/ml of Ionomycine. 
Prior to acquisition, all samples were filtered to remove cell aggregates (41 µm 
mesh; Reichelt Chemietechnik). Data were acquired on a FACSCalibur flow cytometer (BD 
Bioscience) with two lasers (488 and 633 nm) or on a FACSCanto II flow cytometer (BD 
Bioscience) with three lasers (488, 633 and 405 nm) and analyzed with FlowJo software 
(TreeStar, Ashland, OR, USA). For some experiments, LCs and spleen DCs were sorted on 
the FACSAria flow cytometer (BD Bioscience) after MACS® purification. 
 
IV.2.1.3 Ex vivo manipulations of spleen, lymph node and bone marrow 
cells 
IV.2.1.3.a Organ preparation 
 
Mice were sacrificed by cervical dislocation or CO2 asphyxia, fixed with needles on 
a styrofoam pad, disinfected with 70 % ethanol and cut open. Lymph nodes, spleens and leg 
bones were harvested with fine tweezers and kept on ice in RPMI medium.  
 29 
Lymph nodes and spleens were placed on a cell strainer (100 µm, BD) on a 50 ml 
tube and mashed with a 1 ml syringe plunger. For optimal recovery of DCs, organs were 
first enzymatically digested: the mashed organ was incubated for 20 min at 37°C in a 
solution containing 0.1 mg/ml of Liberase DL and 0.2 mg/ml of DNase I (both from 
Roche), followed by a second mechanical dispersion using a cell strainer.  
For bone marrow cell preparation, the hind legs were removed. The bones were 
cleaned from muscles, separated into tibia and femur and disinfected with 70 % ethanol. 
Terminal parts of bones were cut and the bone marrow was flushed out with needle and 
syringe. For large-scale isolation, bones in medium were carefully fragmented with a mortar 
and pestle. The cell suspension was then filtered through a cell strainer. 
 
IV.2.1.3.b Erythrocyte lysis 
 
Erythrocytes from peripheral blood were lyzed using Pharm Lyse reagent (BD) 
according to the manufacturer’s instructions. 
Cell pellets from spleens were incubated in 1 ml of ACK buffer (IV.1.6) for 5 min at 
room temperature (RT). Afterwards, 15 ml PBS was added, the cells were centrifuged and 
resuspended in the appropriate buffer or medium for the following use of the cells.  
Bone marrow erythrocytes were lysed with the Mouse Erythrocyte Lysing Kit from 
R&D System, according to the manufacturer’s instructions. 
 
IV.2.1.3.c Ex vivo T cell proliferation induced by spleen CD8+ DCs 
 
Cells purified with the CD8+ DCs isolation kit of Miltenyi Biotec were incubated 
with OVA-AF647 as described in IV.2.1.2.d. After intensive wash, cells were stained to 
know the amount of CD8+ DCs among the isolated cells. 7x103 CD8+ DCs were co-cultured 
with CFSE labeled OT-I or OT-II cells at a 1 to 10 ratio of DCs to T cells in culture 
medium plus 20 ng/ml of GM-SCF in 96 WP with U-bottom. Proliferation was analyzed by 
CFSE dilution after 3 or 4 days respectively. 
 
IV.2.1.3.d BMLC culture 
 
Bone marrow cells were seeded at 105 cells per ml of culture medium with 7.5 ng/ml 
of GM-CSF, 2.5 ng/ml of TGF-β and 5 ng/ml of SCF. After 3 and 7 days, medium was 
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changed and cells were split for further expansion in the same cocktail as the first day. After 
13 days, cells were matured in culture medium with 10 ng/ml of GM-CSF, 10 ng/ml of 
TNF-α and 10 ng/ml of IL-4. At day 17, more than 90 % of the cells were LC-like cells. 
Except GM-SCF, all these molecules were purchased by Peprotech. 
 
IV.2.1.4 Ex vivo manipulations of skin cells 
IV.2.1.4.a Isolation of epidermal cells 
 
Ears were removed. The dorsal and ventral layers were separated with fine forceps 
and incubated dermal face down in 2 U/ml of Dispase II (Roche) in HBSS in 24 WP for 90 
min at 37°C. Skin sheets were separated into dermis and epidermis with fine forceps in cold 
PBS. Epidermal sheets were further incubated for 2 hours at 37°C in HBSS with 157 U/ml 
of collagenase IV (Worthington) and 10 % FCS in 24 WP. Dermal sheets were digested for 
2 hours at 37°C in a solution containing 0.5 mg/ml of DNase I, 2.7 mg/ml of Collagenase 
XI, 27 µg/ml of Hylaronase VI and 10 mM of Hepes in RPMI. 
The suspensions were passed through a cell strainer and the sheets were mashed on 
the cell strainer to obtain a homogenous cell suspension. The cells were washed and 
counted. They were then either directly stained, used for experiments or further cultured. 
 
IV.2.1.4.b Ex vivo maturation 
 
Epidermal cell suspensions were incubated overnight in culture medium with 20 
ng/ml of GM-SCF with or without 20 µg/ml of peptidoglycan (InvivoGen) in 24 WP. At the 
indicated time points, cells were stained for flow cytometry analysis or used to isolate 
mRNA (IV.2.2.4). 
 
IV.2.1.4.c Crawl out assay 
 
Ears were removed, ventral and dorsal layers were separated and incubated in 500 µl 
of complete medium with 100 ng/ml of CCL21 (R&D Systems) in 24 WP. Every day, 
migrated cells were collected and epidermal sheets were placed in fresh complete medium 
with CCL21, for a total of 3 days. 
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IV.2.1.4.d Ex vivo T cells proliferation induced by Langerhans cells 
 
Epidermal sheets were incubated overnight in 2 ml of culture medium with 500 
µg/ml of OVA grade VII in 24 WP. On the next day, migrated cells and epidermal sheets 
were intensively washed and placed in culture medium with 20 ng/ml of GM-CSF for two 
other days to crawl out. Migrated cells were collected and counted. Some cells were stained 
to assess LCs purity and concentration.  
Cells were resuspended in 200 µl of culture medium with 20 ng/ml of GM-SCF in 
U-bottom 96 WP with CFSE-labeled OT-I or OT-II cells at a ratio of 1:20 of LCs to T cells. 
Proliferation was analyzed by CFSE dilution 3 and 4 days later respectively. 
 
IV.2.1.4.e Histology of ear sheets 
 
Ears were cut, dorsal and ventral layers were incubated with dermal side down in 
0.5 M of PBS-NH4SCN for 20 min at 37°C. Epidermis was carefully separated from dermis 
and fixed on glass slides in acetone at RT for 5 min. Epidermis was washed in PBS and 
incubated in 100 µl of blocking solution (PBS with 0.25 % BSA and 10 % FCS) for 30 min 
in a humidified box. Sheets were then incubated for 30 min in 100 µl of blocking solution 
with FC-block and biotinylated anti-I-Ab. After three washes in PBS, sheets were incubated 
30 min in blocking solution with streptavidin-AF555 and 1 µg/ml of DAPI. Slides were 
washed in PBS. Finally, 100 µl of fluoromount G (Biozol) were added and the coverslip 
was mounted. Slides were kept at 4°C. 
 
IV.2.2 Molecular biology methods 
IV.2.2.1 Agarose gel electrophoresis 
 
This technique was used to separate DNA fragments according to their length. The 
different fragments were identified by comparison to a 100 bp ladder (New England 
Biolabs, Ipswich, MA, USA). Separation was carried out by application of constant voltage 
(80 V) to an electrophoresis chamber containing conductive buffer (TAE, IV.1.6). A 1 % 
agarose gel was used. DNA was visualized by addition of ethidium bromide to the gel (0.5 
µg/ml) and subsequent examination under UV light (312 nm, Intas, Goettingen, Germany).  
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IV.2.2.2 Polymerase chain reaction 
 
The polymerase chain reaction (PCR) is a method used to amplify a piece of DNA 
across several orders of magnitude, generating thousands to millions of copies of a 
particular DNA sequence. 
The DNA polymerase synthesizes new strands of DNA complementary to the 
offered template strand. Primers (IV.1.7) specific for the 5´ and 3´ ends of the DNA target 
were used. The DNA is first denaturized at a high temperature to separate the two strands of 
DNA, then the temperature goes down to allow both primers to hybridize with the target 
sequence as well as the DNA polymerase to synthesize the supplementary strand. Each step 
is repeated several times to expend exponentially the targeted DNA sequence. 
 
Digestion of tail pieces for genotyping: 
50 µl digestion mix (IV.1.6), 2 millimeters tail 
6 hours at 55°C, 5 minutes 95°C, resting at 4°C 
 
PCR mix: 
0.2 µl Primer 5´ (100 pmol/µl) and 0.2 µl Primer 3´ (100 pmol/µl) 
12.5 µl ReadyMix PCR Mastermix (Thermo Fisher scientific) 
2.0 µl DNA 
H2O to reach 25 µl  
 
PCR Rac1N17 Rac1-flox CD11c- and 
Langerin-Cre 
Reverse 
Transcriptase-PCR 
Step1 5 min at 95°C 5 min at 95°C 5 min at 95°C 10 min at 95°C 
Step2 30 snd at 95°C 30 snd at 94°C 30 snd at 95°C 10 snd at 95°C 
Step3 45 snd at 55°C 30 snd at 63°C 30 snd at 55°C 30 snd at 60°C 
Step4 30 snd at 72°C 30 snd at 72°C 45 snd at 72°C cycling 90 times 
from Step2 
Step5 cycling x29 
from Step2 
cycling x10 from 
Step2, at each cycle 
-1°C for Step3  
cycling x35 from 
Step2 
30 snd at 40°C 
Step6 10 min at 72°C 30 snd at 94°C 5 min at 72°C resting at 4°C 
Step7 resting at 4°C 30 snd at 53°C resting at 4°C  
Step8  30 snd at 72°C   
Step9  cycling x35    
Step10  Resting at 4°C   
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IV.2.2.3 Western blot 
 
Approximately 106 CD11c+ MACS-sorted splenocytes were lysed for 15 min in 
lysis buffer on ice with constant vortexing. Protein concentration was determined with the 
Quant-iTTM protein assay kit (Invitrogen). Then 15 µg of protein were reduced in a 5 % 
SDS solution for 10 min at 95°C. Protein samples were loaded on a 5–12% gradient gel 
(Bio-Rad) (IV.1.6) and let run for 2 hours at 80 V. Transfer on nitrocellulose membrane 
was performed for 90 min at 70 V. Membranes were blocked overnight in blocking solution 
(IV.1.6 and IV.1.2). For the detection of several proteins of the same size, the membrane 
was stripped 30 min in stripping buffer (IV.1.6) and then blocked again. Proteins were 
detected with the antibodies described in section IV.1.2. To control for cell loading, blots 
were subsequently stained with anti–β-actin antibody. Signal intensities were quantified 
with ImageJ software (National Institutes of Health, Bethesda, MD).  
 
IV.2.2.4 mRNA isolation and cDNA generation 
 
The RNeasy Micro Kit (Qiagen, Hilden, Germany) was used according to the 
manufacturer’s instructions. During RNA isolation, residual amounts of DNA were 
removed by on-column DNase I treatment.  
Nucleic acid concentrations were determined by UV absorbance measurement at 
260 nm with a NanoDrop device (Thermo Fisher Scientific, Waltham, MA, USA). The 
260/280 ratio is an indicator for nucleic acid purity: values between 1.8 and 2 are desirable, 
because it represents a low protein contamination. The mRNA was either frozen at -80°C or 
directly reverse transcribed into cDNA. 
The mRNA was reverse transcribed using SuperScript III First-StrandSynthesis 
System using random hexamers (Invitrogen). To standardize the qPCR, 200 ng mRNA was 
used. The cDNA was either frozen at -20°C or directly used for quantitative PCR (qPCR). 
 
IV.2.2.5 Quantitative PCR 
 
Quantitative PCR is used to determine the concentration of a particular cDNA 
sequence within a sample. The TaqMan method of cDNA detection is based on probe use. 
These probes are oligonucleotides labeled with fluorescent dyes, which give a signal only 
when the probes are bound to their specific DNA sequences. The initial amount of the 
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targeted DNA is correlated with the number of cycles (crossing point, CP value) that is 
reached when fluorescence intensity exceeds a certain threshold. 
The TaqMan assay was performed with the LightCycler TaqMan Master Kit 
(Roche) and the Universal ProbeLibrary Set mouse (Roche) according to the manufacturer’s 
instructions, on a CFX96 Real Time System (BIO-RAD). Primers and probes are listed in 
IV.1.7. Expression levels were normalized to HPRT and relative quantification was 
calculated using the ΔΔCT-method (Livak and Schmittgen, 2001). 
 
IV.2.2.6 Generation of ovalbumin-coated polystyrene beads 
 
The polystyrene microparticles of 2 µm of diameter from Polysciences, Inc were 
coated with OVA as indicated in their technical datasheet. This is not a covalent coating. 
The beads have a slight anionic charge because of sulfate ester groups, allowing adsorbtion 
of proteins. 
Briefly, 0.5 ml of a 2.5 % beads suspension were washed and incubated overnight 
with 500 µg of OVA grade VII in borate buffer (IV.1.6). The supernatant was harvested to 
determine the concentration of uncoupled protein. It allows the determination of OVA 
concentration on the beads. Free spaces on the beads were blocked 3 times in 10 mg/ml of 
BSA in borate buffer for 30 min. The pellet was resuspended in 1 ml of storage buffer 
(IV.1.6) and stored at 4°C. Before use, the appropriate volume of beads was washed 3 times 
in PBS and resuspended in the appropriate volume of PBS (5 µg of OVA-coated beads in 
30 µl). 
 
IV.2.2.7 MMP-9 ELISA on BMLC culture supernatant 
 
BMLC culture supernatants were concentrated with Centricon®Plus-70 (Millipore). 
The concentration efficiency is the ratio between the initial volume and the final 
concentrated volume of supernatant. Samples were used in an ELISA (R&D Systems) to 
determine the concentration of total MMP-9. MMP-9 concentration in undiluted 
supernatants corresponds to the concentration in concentrated supernatants determined 
according to manufacturer’s instruction divided by the concentration efficiency. 
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IV.3 STATISTICAL ANALYSIS 
 
Data were analyzed using the Student’s t test (GraphPad Prism 5.0b; GraphPad 
Software). P-values were defined as: ***: p<0.001, **: p=0.001 to 0.01, *: p=0.01 to 0.05. 
Error bars represent standard deviations. All experiments were repeated at least three times, 
with at least 3 mice per group, unless otherwise stated. 
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V RESULTS 
V.1 CHARACTERIZATION OF LCs IN Rac1N17 MICE 
V.1.1 Characterization of epidermis, dermis and sdLNs 
 
Spleen DCs expressing a dominant negative form of the Rho-GTPase Rac1 
(Rac1N17) are known to have uptake and cross-presentation defects (Kerksiek et al., 2005; 
Neuenhahn et al., 2006; Luckashenak et al., 2008). We were wondering if this was also the 
case for epidermal LCs, and if so, we could use these mice to investigate the controversial 
role of LCs in skin immune responses. 
First, we verified that Rac1N17 LCs express the dominant negative variant of Rac1. 
The Rac1N17 cDNA is from canine origin (Chavrier et al., 1990; Dutartre et al., 1996; 
Guillemot et al., 1997; Franco et al., 1999) and it has 90 % similarity with the murine 
sequence at the mRNA level and 100 % at the protein level. The use of primers specific for 
the canine sequence of Rac1 revealed the presence of Rac1N17 mRNA in Rac1N17 spleen 
DCs and Rac1N17 LCs (Figure 9). This means that the dominant negative variant of Rac1 
is expressed in Rac1N17 but not in WT LCs.  
 
 
Figure 9: Rac1N17 mRNA is expressed in Rac1N17 LCs 
WT and Rac1N17 spleen DCs (as positive control) and LCs were sorted by flow cytometry, mRNA was 
isolated and reverse transcribed. Rac1N17 cDNA was amplified with primers specific for canine Rac1 
(Rac1N17 3’ and Rac left 5’, see IV.1.7). The absence of genomic DNA contamination was assessed by a 
control sample that was not reverse transcribed. The markers show DNA size in bp, the expected product has 
240 nucleotides. 
 
Next, in order to determine the frequency of LCs in the skin, we analyzed Rac1N17 
and WT epidermis by histology and flow cytometry. Rac1N17 and WT LCs were present in 
comparable amounts in the epidermis, as detected by both methods (Figure 10.A). The 
dermal sheets were enzymatically digested and dermal cells were stained for flow 
cytometry analysis. Here, LCs (defined in the dermis as CD45+ CD11c+ MHC-II+ Langerin+ 
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CD103- (Bursch et al., 2007)) were found reduced by half in Rac1N17 dermis as compared 
to WT (Figure 10.B). 
 
 
Figure 10: Rac1N17 LCs in steady state skin 
A, Upper panel: epidermis was stained with anti-MHC-II antibody and positive cells were counted. Images 
were acquired at original magnification x200. Scale bar, 50 µm. Lower panel: epidermis and dermis were 
separated, epidermis was further enzymatically digested and LCs were analyzed by flow cytometry (identified 
as CD45+ CD11c+ MHC-II+ Epcam+ cells, red gate). B, Epidermis and dermis were separated, dermis was 
further enzymatically digested and LCs were analyzed by flow cytometry (red gate). Statistics represent the 
frequency of LCs inside the DC population. Data are representative of 3 independent experiments. Groups 
were compared by unpaired t test: not significant p>0.05; * 0.01>p>0.05. 
 
Finally, we investigated the number of LCs in sdLNs. The global migratory DC 
population (CD11c+ MHC-IIhigh cells, (Salomon et al., 1998; Henri et al., 2001)) was 
significantly reduced in Rac1N17 mice (Figure 11, upper panels). Within this population, 
Rac1N17 LCs were even more reduced in proportions (8.6 % ± 1.5 of migrating DCs in 
Rac1N17 mice as compared to 28.1 % ± 2.7 in WT mice, Figure 11, lower panels), leading 
to an overall 2.5 fold decrease of migratory LC numbers in the Rac1N17 sdLNs. Langerin+ 
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dDCs (Langerin+ CD103+) were even more decreased in sdLNs of Rac1N17 mice (for more 
details see V.2.1). 
From these data, we conclude that Rac1N17 LCs develop normally but have a defect 
in migration at the steady state.  
 
 
Figure 11: Rac1N17 LCs in steady state skin draining lymph nodes 
Inguinal and axillary LNs were enzymatically digested. Cells were then stained and analyzed by flow 
cytometry. Upper panels represent migratory DCs (CD11c+ MHC-IIhigh, red gate) among total LN cells. 
Dermal and epidermal DCs were identified in the lower panels according to their expression of CD103 and 
Langerin. Statistics represent the number of LCs in sdLNs. Data are representative of 3 different experiments; 
groups were compared by unpaired t test: not significant p>0.05; * 0.01>p>0.05.  
 
V.1.2 Functional analysis of Rac1N17 LCs 
 
Next we investigated whether Rac1N17 LCs could be activated. Epidermal cells 
were activated overnight in the presence of GM-CSF and up-regulation of MHC-I, MHC-II, 
CD40, CD80 and CD86 was analyzed. We could not detect differences between Rac1N17 
and WT LC activation state (Figure 12.A). 
Then, we tested if Rac1N17 LCs have the same uptake defect as detected in 
Rac1N17 spleen DCs (Kerksiek et al., 2005). Non-activated epidermal cells were incubated 
for 40 minutes with either FITC-dextran (mannose-receptor mediated endocytosis), 
luciferase yellow (fluid phase endocytosis: pinocytosis) or OVA-AF647 (both mannose-
receptor mediated endocytosis and pinocytosis, pH insensitive fluorochrome). Rac1N17 
LCs did not display any uptake defect at the concentrations and time points used in this 
study (Figure 12.B). 
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Figure 12: Activation, uptake of soluble molecules and T cell priming are normal in Rac1N17 LCs 
A, Epidermal cells were incubated overnight with GM-SCF. Up-regulation of MHC-I, MHC-II, CD40, CD80 
and CD86 was assessed directly after cell isolation (gray filled histogram) and after 12 hours of GM-CSF-
induced maturation. Rac1N17: full line; WT: dotted line. LCs were identified as CD45+ CD11c+ MHC-II+ 
Epcam+ cells. B, Epidermal cells were incubated for 40 minutes with either 250 µg/ml FITC-dextran, 500 
µg/ml luciferase yellow or 5 µg/ml OVA-AF647. Rac1N17: full line; WT: dotted line; gray filled histogram: 
4°C control. LCs were identified as CD45+ CD11c+ MHC-II+ Epcam+ cells. C, Epidermal sheets were 
incubated for 12 hours with peptide free OVA, washed intensively the next day and put in culture medium 
with GM-SCF for 2 other days of crawl out. After crawl out, migrated LCs were co-cultured with CFSE-
labeled OT-I or OT-II cells. T cell proliferation was assessed by measuring CFSE dilution 3 and 4 days later, 
respectively. Rac1N17: full line; WT: dotted line; gray filled histogram: no antigen control. OT-II and OT-I T 
cells were identified as CD90.1+ CD4+ and CD90.1+ CD8+ cells respectively. Data are representative of 5 (A), 
3 (B) and 6 (C) independent experiments. 
 
Finally, we examined whether Rac1N17 LCs were able to perform in vitro direct 
MHC-II presentation or MHC-I cross-presentation. Epidermal sheets were incubated with 
peptide free Ovalbumin (OVA) and after crawl out (Stoitzner et al., 2006), migrated LCs 
were co-cultured with either CFSE-labeled OT-I or OT-II cells (CD8+ and CD4+ T cells 
recognizing the OVA peptides presented on MHC-I and MHC-II in C57BL/6 mice 
respectively). Both CD4+ and CD8+ T cell proliferations were similarly induced by 
Rac1N17 and WT LCs (Figure 12.C). From this assay, we concluded that Rac1N17 LCs 
have no defect in MHC-II presentation and cross-presentation. 
Although transgenic canine Rac1N17 is expressed in the Rac1N17 LCs, Rac1N17 
LCs are present in normal numbers in Rac1N17 skin, can be activated, take up antigen 
normally and can initiate both CD4+ and CD8+ T cell responses. Rac1-dependent functions 
in spleen DCs appear to be Rac1-independent in LCs.  
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V.1.3 Migratory behaviour 
 
Rac1 is responsible for a wide range of functions depending on the cell type (Vega 
and Ridley, 2008). It controls uptake, processing (Heasman and Ridley, 2008) and 
migration (Swetman et al., 2002) in phagocytes. We have already showed that Rac1N17 
LCs perform normal antigen uptake and presentation, and have a migration defect at the 
steady state. Therefore, we next investigated the migratory behaviour of these cells in 
inflammatory conditions. 
We first performed an in vivo FITC painting assay (Macatonia et al., 1986). Briefly, 
FITC was painted on the abdomen of mice and sdLNs were harvested four days later. The 
global MHC-IIhigh (migratory DCs) FITC+ population represented 0.15 % ± 0.04 of sdLN 
cells in Rac1N17 mice, whereas WT sdLNs contained 0.33 % ± 0.1 of these migratory cells 
(Figure 13.A, upper panel). Within this population, Rac1N17 LCs were even more reduced 
proportionally (56.2 % ± 3.4 of FITC+ DCs in Rac1N17 mice as compared to 75.7 % ± 5 in 
WT mice), leading to an overall 3.5 fold decrease in migrating LC numbers in the Rac1N17 
sdLNs (Figure 13.A, lower panel and bar graph). Furthermore, CD103+ Langerin+ dDCs 
also had a migratory defect (Figure 13.A, and more detailed in Figure 23). We conclude 
that Rac1 is required for LC and Langerin+ dDC migration. 
 
 
Figure 13: Impaired LC migration under inflammatory conditions (Figure legend continues) 
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A, In vivo FITC painting: A solution of 2 mg FITC in a 1:1 mix of acetone : dibutylphthalate was applied on 
the shaved abdomen of the mice. Four days later, the inguinal and axillary LNs were analyzed by flow 
cytometry. The red gates from upper panels indicate FITC+ MHC-II+ cells according to the unpainted control. 
The red gates from lower panels indicate FITC+ LCs (Langerin+ CD103- from FITC+ MHC-IIhigh cells). 
Statistics represent the number of FITC+ LCs. B, In vitro crawl out assay: Total skin explants were floated on 
medium in the presence of CCL21. After three days, the migrated DCs were stained and analyzed by flow 
cytometry (gated on CD45+ CD11c+ MHC-II+ cells). Red gates from representative flow cytometry plots and 
statistics indicate the frequency of LCs inside the DC population. Data are representative of 3 (A) and 4 (B) 
independent experiments; groups were compared by unpaired t test: not significant p>0.05; * 0.01>p>0.05; ** 
0.001>p>0.01.  
 
Second, we performed an in vitro crawl out assay (Stoitzner et al., 2003), where 
total skin (dermis and epidermis) floats for three days on culture medium in the presence of 
CCL21. Migrated cells were counted and analyzed by flow cytometry. As shown in Figure 
13.B, there were almost two times less LCs migrating out from Rac1N17 skin in response to 
chemoattractant as compared to WT. Similarly, Langerin+ dDCs did also have a migration 
defect (Figure 13.B and Figure 22). These results suggest that LCs require Rac1 for 
migration, which results in reduced numbers of Rac1N17 LCs in sdLNs in the steady state 
(Figure 11) as well as upon activation (Figure 13).  
Finally, we further investigated the migratory defect of Rac1N17 LCs. We isolated 
Rac1N17 and WT epidermis and placed it in culture medium in the presence of CCL21 for 
three days, in order to assess the ability of LCs to leave the epidermis. As shown in Figure 
14, the amount of harvested LCs was comparable between Rac1N17 and WT epidermis.  
Therefore, we concluded that Rac1N17 LCs can migrate out of the epidermis, when 
the dermis is absent, but not of total skin. 
 
 
Figure 14: Rac1N17 LCs migrate normally from epidermis 
In vitro epidermis crawl out assay: epidermis was floated on medium in the presence of CCL21. After three 
days, the migrated cells were stained and analyzed by flow cytometry (first gated on CD45+ MHC-II+ cells on 
upper graph, then on CD11c+ Epcam+ cell on lower graph). Statistics represent (Figure legend continues) 
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frequency of LCs inside the CD45+ MHC-II+ population. Data are representative of 6 independent 
experiments; groups were compared by unpaired t test: not significant p>0.05.  
 
V.1.4 Molecules required to exit the epidermis 
 
When the dermis is separated from the epidermis through Dispase II digestion, the 
DEBM remains attached to the dermis (Oakford et al., 2011). Therefore, we have 
hypothesized that LCs cannot migrate through the DEBM, which would explain the 
different outcomes obtained from the two crawl out assays (total skin in Figure 13 versus 
epidermis in Figure 14). 
When LCs get activated, they down-regulate the surface expression of several 
markers, first to detach from the keratinocytes and then to become insensitive to skin 
homing (Sallusto et al., 1998). For this reason, we investigated the down-regulation of E-
cadherin and CCR5 on LCs upon maturation. As shown in Figure 15.A, Rac1N17 and WT 
LCs modulated to the same extent the surface level of these molecules. To leave the 
epidermis, LCs also need to up-regulate integrins that bind DEBM, chemokine receptors for 
LN homing and other molecules important for the interaction with matrix substrates. 
Therefore, we tested the up-regulation of α6-integrin, CCR7, CXCR4 and CD44 by 
activated LCs, but we could not detect differences between the surface levels of these 
markers on Rac1N17 or WT LCs both before or after maturation (Figure 15.A). 
The absence of TGF-β induces LCs to exit the epidermis (Kaplan et al., 2007). Upon 
activation, LCs produce pro-inflammatory IL1-β, which in turn induces the release of the 
proinflammatory cytokines TNF-α and IL1-α by keratinocytes. TNF-α and IL1-α are 
produced only by keratinocytes whereas TGF-β and IL1-β are exclusively produced by 
LCs. Therefore, we investigated the expression level of these cytokines in the epidermis 
before and during activation. As expected, IL1-β expression was increasing upon activation, 
but there was no difference between the IL1-β level of Rac1N17 and WT epidermis (Figure 
15.B, lower graph). TGF-β expression did not change over time (Figure 15.B, upper 
graph), meaning that its absence is sufficient (Kaplan et al., 2007), but not nessecary for 
LCs to exit from the epidermis. Rac1N17 LCs produced as much IL1-β and TGF-β as WT 
LCs upon activation. 
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Figure 15: The molecular machinery required for Rac1N17 LC migration is normally regulated 
A, Epidermal cells were activated in culture medium with GM-CSF and peptidoglycan (TLR2 ligand) for 18 
hours (CCR7, CD44) or 66 hours (CXCR4, CCR5, E-cadherin, α6 integrin). These incubation times were 
determined after a time course experiment. Rac1N17: full line; WT: dotted line; gray filled histogram: before 
activation. LCs were identified as CD45+ CD11c+ MHC-II+ Epcam+ cells. B, Epidermal cells were activated in 
culture medium with GM-CSF and peptidoglycan. At the indicated time, a third of the culture was harvested 
(D0: before activation). mRNA was isolated and reverse transcribed. Quantitative PCR was performed for 
TGF-β and IL1-β. Expression levels are relative to HPRT mRNA level. C, Bone marrow cells were cultured 
and differentiated into LCs. Supernatants were harvested after 13 days (after expansion) and 17 days (after 
terminal differentiation) of culture. Supernatants were concentrated and total MMP-9 ELISA was performed. 
Data are representative of 4 independent experiments. Groups were compared by unpaired t test: not 
significant p>0.05; * 0.01>p>0.05; ** 0.001>p>0.01; *** p<0.001. 
 
Matrix metalloproteinases (MMPs) are important to digest the extracellular matrix 
and MMP-9 was identified as one of the key MMPs required to digest the DEBM 
(Ratzinger et al., 2002). In the epidermis, LCs are not the only cells producing MMPs. 
Given the small number of LCs in mouse epidermis and the necessity to FACS-sort these 
cells in order to study MMP production, it would require a high amount of mice to isolate 
enough LCs. Therefore, we decided to generate bone marrow derived Langerhans cells 
(BMLCs, (Merad et al., 2000)). The cells proliferated for 13 days in a cocktail of GM-CSF, 
TGF-β and SCF. On day 13 of culture, they received differentiation cytokines (GM-SCF, 
TNF-α and IL-4) to become LC-like cells (more than 90 % of the cells at day 17 express LC 
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markers, data not shown). MMP-9 concentation in supernatants of day 13 (as negative 
control) and day 17 was determined. As shown in Figure 15.C, Rac1N17 BMLCs produced 
the same proportion of MMP-9 as WT BMLCs. 
In summary, none of the molecules required for LC migration we have tested was 
differentially regulated in Rac1N17 LCs. 
 
V.1.5 Role of LCs in skin immune responses 
 
Skin dLNs of Rac1N17 mice have the following phenotype: migratory skin derived 
DCs and particularly LCs show an impaired migration capacity; resident DCs (related to 
spleen DCs, (Guilliams et al., 2010)) have uptake and cross-presentation defects. Therefore, 
we expected an impaired T cell priming to skin immunization. 
In order to investigate the role of LCs in T cell priming, we generated bone marrow 
chimeras, as LCs resist irradiation (Merad et al., 2002). CD45.1 WT or CD45.2 Rac1N17 
mice were irradiated and reconstituted with either CD45.1 WT or CD45.2 Rac1N17 bone 
marrow. Nine weeks after reconstitution, more than 97 % of LCs remained from recipient 
origin in both epidermis and dermis, whereas more than 96 % of dDCs were from donor 
origin (Figure 16, according to CD45 expression that is a hematopoietic cell marker). 
 
 
Figure 16: Skin chimerism of bone marrow chimeric mice (Figure legend continues) 
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A, Epidermis from chimeric mice (WTRac1N17 and Rac1N17WT) was enzymatically digested and LCs 
(CD11c+ MHC-II+ Epcam+) were analyzed for CD45 expression. B, Dermis from chimeric mice was 
enzymatically digested and DCs (CD11c+ MHC-II+) were identified as either LCs or dermal DCs according to 
Epcam expression. These cells were further analyzed for CD45 expression. Data are representative of 8 
independent experiments. 
 
The difference between the first two combinations (Rac1N17Rac1N17 and 
Rac1N17WT, Figure 17.A) was that LCs were WT only in the last combination, whereas 
in both cases all other DC subsets were Rac1N17. Eight weeks after reconstitution, mice 
received CFSE-labeled OT-I cells. The following day, they were immunized intradermally 
with 5 µg of OVA-coated polystyrene beads and 15 µl of acetone were applied on the 
injection site to activate DCs. Five days later, T cell proliferation was assessed by 
measuring CFSE dilution. In the presence of WT LCs, the CD8+ T cells expanded twice 
more than in presence of Rac1N17 LCs (Figure 17.A), both in terms of cell number and 
proliferation. The CFSE dilution profiles of the chimeras were different, but because the 
proportions of non-divided cells (CFSEhigh) were similar, we focus our analysis on cells that 
underwent more than 5 divisions (Figure 17.A, lower dot plots and bar graph, CFSElow). To 
investigate effector functions, we examined the intracellular production of IFN-γ and TNF-
α, but could not detect any differences (Figure 17.B).  
In the reverse chimeras (WTWT and WTRac1N17, Figure 17.C), all DC subsets 
were WT, with either WT LCs or migration-defective LCs. We performed the same 
immunization strategy as described above. The decreased number of LCs in WTRac1N17 
sdLNs did neither significantly impair CD8+ T cell priming (Figure 17.C) nor CD8+ T cell 
effector functions (Figure 17.D). 
Together, these data showed that migratory LCs contribute to CD8+ T cell priming 
upon intradermal immunization when the other DC subsets express Rac1N17, but that this 
contribution does not have a significant impact when the other DCs are derived from WT 
bone marrow. This demonstrates a role of LCs in CD8+ T cell priming. It also shows that 
the presence of WT dDCs is sufficient to overcome the defect of Rac1N17 LCs. So in the 
case of intradermally injected antigen, LCs contribute to CD8+ T cell response but this 
contribution is undetectable when the other DC subsets are functional to take part to the 
response. However, even if LCs play a role in CD8+ T cell priming, they do not influence 
the differentiation of CD8+ T cells. 
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Figure 17: LCs contribute to CD8+ T cell priming 
A and B, only LCs are derived from WT bone marrow; C and D, only LCs express Rac1N17: CD45.2 
Rac1N17 and CD45.1 WT mice were lethally irradiated and received either CD45.2 Rac1N17 or CD45.1 WT 
bone marrow. Eight weeks later, chimeric mice received 1x106 CFSE-labeled OT-I T cells via i.v. injection. 
On the next day, 5 µg of OVA-coated beads were injected i.d. on the flank and 15 µl of acetone were applied 
on the site of immunization. Five days later, inguinal and axillary LNs were harvested and stained. A and C, 
OT-I cells among the LN cells (CD90.1+ CD8+, upper panels, red gate); proliferation was assessed by CFSE 
dilution (lower panels). Statistics show absolute numbers of OT-I T cells and proportions of OT-I cells that 
underwent more than 5 divisions. B and D represent intracellular cytokine stainings of IFN-γ and TNF-α in 
OT-I cells, performed after 4 hours of in vitro restimulation with SIINFEKL peptide. Data are representative 
of 3 independent experiments; groups were compared by unpaired t test: not significant p>0.05; * 
0.01>p>0.05; ** 0.001>p>0.01. 
 
Next, we investigated the role of LCs in CD4+ T cell priming. We generated bone 
marrow chimeras using the same combinations as described above. Eight weeks after 
reconstitution, mice received CFSE-labeled OT-II cells. The following day, they were 
immunized intradermally with 5 µg of OVA-coated polystyrene beads and 15 µl of acetone 
were applied on the injection site to activate DCs. Five days later, T cell proliferation was 
assessed by measuring CFSE dilution. As shown in Figure 18.A and Figure 18.C, CD4+ T 
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cell responses in Rac1N17Rac1N17 and WTWT mice were similar to that observed in 
Rac1N17WT and WTRac1N17 mice, respectively. Examination of IFN-γ and TNF-α 
production by CD4+ T cells revealed identical effector functions in the mixed chimeras and 
their controls (Figure 18.B and Figure 18.D). Therefore, we concluded that in our settings 
LCs do not play a role in CD4+ T cell priming.  
 
 
Figure 18: CD4+ T cell priming is not controlled by LCs  
A and B, only LCs are derived from WT bone marrow; C and D, only LCs express Rac1N17: CD45.2 
Rac1N17 and CD45.1 WT mice were lethally irradiated and received either CD45.2 Rac1N17 or CD45.1 WT 
bone marrow. Eight weeks later, chimeric mice received 2x106 CFSE-labeled OT-II T cells via i.v. injection. 
On the next day, 5 µg of OVA-coated beads were injected i.d. on the flank and 15 µl of acetone were applied 
on the site of immunization. Five days later, inguinal and axillary LNs were harvested and stained. A and C, 
OT-II cells among LN cells (CD90.1+ CD4+, upper panels, red gate); proliferation was assessed by CFSE 
dilution (lower panels). Statistics show absolute numbers of OT-II T cells and proportions of OT-II cells that 
underwent more than 5 divisions. B and D represent intracellular cytokine stainings of IFN-γ and TNF-α in 
OT-II cells, performed after 4 hours of in vitro restimulation with PMA and ionomycin. Data are 
representative of 6 independent experiments; groups were compared by unpaired t test: not significant p>0.05. 
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V.2 ADDITIONAL MOUSE MODELS TO STUDY THE ROLE OF 
Rac1 IN LC FUNCTIONS 
V.2.1 Characterization of epidermis, dermis and sdLNs 
 
The dominant negative protein Rac1N17 blocks GEFs of Rac1, but some of these 
GEFs are also required for the activation of other Rho-GTPases (Figure 7). Therefore, the 
phenotype of spleen and skin Rac1N17 DCs may be the result of the blockade of Rac1 
pathway plus of some pathways controlled by other Rho-GTPases (Feig, 1999). In order to 
focus exclusively on Rac1 in LCs, we bred conditional Rac1-KO mice with mice expressing 
the Cre recombinase under the control of either the CD11c promotor (CD11c-Cre x Rac1-
flox, abbreviated CD11c-Rac1-/-) or the murine Langerin promotor (Langerin-Cre x Rac1-
flox, abbreviated Lang-Rac1-/-). Because we used the murine Langerin promotor in the 
Lang-Rac-/- mice, Rac1 should be deleted in both LCs and Langerin+ dDCs. 
Mice bearing the conditional KO were compared to mice expressing the Cre 
recombinase only (CD11c-Rac1-/- and Lang-Rac1-/- mice were compared to CD11c-Cre and 
Langerin-Cre mice respectively). Because WT mice serve as control for transgenic mice, 
Rac1N17 mice were compared to C57BL/6 mice. 
We first characterized the epidermis of these mice. As shown in Figure 19, LC 
proportions were reduced in both KO mice, which was not the case in Rac1N17 mice. It 
shows the requirement of Rac1 for LC homeostasis. 
 
 
Figure 19: Characterization of CD11c-Rac-/- and Lang-Rac-/- epidermis, compared to Rac1N17 
epidermis 
Epidermis and dermis were separated, epidermis was further enzymatically digested and LCs were analyzed 
by flow cytometry (gated on CD45+ cells, red gate). Statistics represent proportions of LCs in the CD45+ 
population. Data are representative of 3 independent experiments; groups were compared by unpaired t test: 
not significant p>0.05; * 0.01>p>0.05; ** 0.001>p>0.01, *** p<0.001. Tg: transgenic Rac1N17; KO: 
Knockout Rac1-/-. 
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Surprisingly, LCs from Rac1N17 mice and its control were present in lower 
amounts in the epidermis than LCs from the other strains. This suggests that the different 
strains have specific differences, even if they are all on the C56BL/6 background. 
We then characterized the dermis of these mice. LCs were reduced in both KO 
strains and Rac1N17 mice (Figure 20, panels and upper bar graph), whereas there were no 
differences in Langerin+ dDC proportions (Figure 20, panels and lower bar graph). This 
suggests that Rac1 is not required for Langerin+ dDC homeostasis.  
 
 
Figure 20: Characterization of CD11c-Rac-/- and Lang-Rac-/- dermis, compared to Rac1N17 dermis 
Epidermis and dermis were separated, dermis was further enzymatically digested and LCs and Langerin+ 
dDCs were analyzed by flow cytometry (gated on CD45+ CD11c+ MHC-II+ cells, red gates). Statistics 
represent the frequency of LCs (upper bar graph) and of Langerin+ dDCs (lower bar graph) inside the DC 
population. Data are representative of 3 independent experiments; groups were compared by unpaired t test: 
not significant p>0.05; * 0.01>p>0.05; ** 0.001>p>0.01, *** p<0.001. Tg: transgenic Rac1N17; KO: 
Knockout Rac1-/-. 
 
We were expecting a decrease of both, LCs and Langerin+ dDCs in the sdLNs of 
KO mice, similar to what was observed in Rac1N17 mice (Figure 11). Indeed, we saw an 
overall 40 % decrease of migratory DCs in both KO strains and Rac1N17 mice as compared 
to control mice (Figure 21, upper panels). Within this population, KO LCs were reduced 
compared to controls (Figure 21, lower panels and upper bar graph). Langerin+ dDCs from 
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CD11c-Rac1-/- and Lang-Rac1-/- mice were decreased compared to controls but lacked 
significance (Figure 21, lower panels and bar graphs). 
Taken together, these data indicate that Rac1 is required for the homeostasis and the 
steady state migration of LCs but not of Langerin+ dDCs.  
 
 
Figure 21: Characterization of CD11c-Rac-/- and Lang-Rac-/- sdLNs, compared to Rac1N17 sdLNs 
Inguinal and axillary LNs were enzymatically digested. Cells were then stained and analyzed by flow 
cytometry. Upper panels represent migratory DCs (CD11c+ MHC-IIhigh, red gate) among total LN cells. 
Dermal and epidermal cells were identified in the lower panels according to their expression of CD103 and 
Langerin (red gates). Statistics represent the number of LCs and Langerin+ dDCs in sdLNs. Data are 
representative of 3 independent experiments; groups were compared by unpaired t test: not significant p>0.05; 
* 0.01>p>0.05. Tg: transgenic Rac1N17; KO: Knockout Rac1-/-. 
 
V.2.2 Migratory behaviour 
 
Because analysis of steady state sdLNs of CD11c-Rac1-/- and Lang-Rac1-/- mice 
showed reduced LC numbers (Figure 21) and because we previously showed that Rac1N17 
LCs have a migratory defect also in inflammatory conditions, we assumed a similar 
phenotype in CD11c-Rac1-/- and Lang-Rac1-/- mice.  
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Therefore, we first tested DC emigration from total skin with an in vitro crawl out 
assay. As expected, LCs and Langerin+ dDCs from both KO and Rac1N17 mice were 
unable to migrate out of the skin (Figure 22).  
 
 
Figure 22: In vitro migration of CD11c-Rac-/- and Lang-Rac-/- skin DCs, compared to Rac1N17 skin DCs 
Total skin explants were floated on medium in the presence of CCL21. After three days, the migrated cells 
were stained and analyzed by flow cytometry (gated on CD45+ CD11c+ MHC-II+ cells). Representative flow 
cytometry plots and statistics represent proportions of dermal and epidermal cells inside the DC population. 
Data are representative of 3 independent experiments; groups were compared by unpaired t test: not 
significant p>0.05; * 0.01>p>0.05; ** 0.001>p>0.01; *** p<0.001. Tg: transgenic Rac1N17; KO: Knockout 
Rac1-/-. 
 
Next, we investigated the in vivo migratory behaviour of LCs and Langerin+ dDCs 
of the KO mice by performing a FITC painting assay. Again we observed an overall 
decrease in the proportions of FITC+ MHC-IIhigh cells in all groups (Figure 23, upper 
panel). Within this FITC+ DC population, the numbers of migratory LCs from all mice were 
reduced compared to controls (Figure 23, lower panel and upper bar graphs). While 
CD11c-Rac1-/- Langerin+ dDCs numbers were also diminished, Lang-Rac1-/- sdLNs 
contained as many migratory Langerin+ dDCs as control sdLNs (Figure 23, lower panel 
and upper bar graphs). 
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Figure 23: In vivo migration of CD11c-Rac-/- and Lang-Rac-/- skin DCs, compared to Rac1N17 skin DCs 
A solution of 2 mg FITC in a 1:1 mix of acetone : dibutylphthalate was applied on the shaved abdomen of the 
mice. Four days later, the inguinal and axillary LNs were analyzed by flow cytometry. Upper panels represent 
FITC+ migratory DCs (FITC+ MHC-IIhigh, red gate) among total LN cells, according to unpainted controls. 
Dermal and epidermal cells were identified in the lower panels according to their expression of CD103 and 
Langerin. Statistics represent the number of FITC+ LCs and FITC+ Langerin+ dDCs in sdLNs. Data are 
representative of 3 independent experiments; groups were compared by unpaired t test: not significant p>0.05; 
* 0.01>p>0.05; ** 0.001>p>0.01; *** p<0.001. Tg: transgenic Rac1N17; KO: Knockout Rac1-/-. 
 
In summary, the three different models used to study the role of Rac1 in LCs 
showed the same migratory defect both in vivo and in vitro. The Langerin+ dDCs of the 
three strains, present in the dermis in similar amounts as compared to control mice, 
displayed an in vivo migration defect in CD11c-Rac1-/- and Rac1N17 mice, but not in Lang-
Rac1-/- mice. 
 
V.2.3 T cell response to skin immunization 
 
Having detected this migration defect in Langerin+ APCs, we next wanted to test the 
impact of migration defective LCs and Langerin+ dDCs on T cell priming. CFSE-labeled 
OT-I cells were injected i.v. into mice. One day later, 5 µg of OVA-coated polystyrene 
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beads were injected intradermally and 15 µl of acetone were applied on the injection site to 
activate DCs. T cell proliferation was assessed by measuring CFSE dilution five days later.  
As expected from previous experiments (Figure 17, (Kerksiek et al., 2005; 
Neuenhahn et al., 2006)), CD8+ T cell priming was impaired in Rac1N17 mice (Figure 24). 
It can be explained by the migration defect of LCs and Langerin+ dDCs, as well as by the 
cross-presentation defect in lymph node resident CD8+ DCs (Luckashenak et al., 2008).  
In CD11c-Rac1-/- mice, T cell proliferation was not significantly decreased, despite 
the migration defect of LCs and Langerin+ dDCs. Therefore, Rac1 deletion affects LC and 
Langerin+ dDC migration without decreasing skin CD8+ T cell response.  
Additionally, we did not detect any defect in CD8+ T cell priming in Lang-Rac1-/- 
mice. Therefore, we concluded that the migration defect of Lang-Rac1-/- LCs is not 
sufficient to influence CD8+ T cell response to intradermally injected particulate antigen. 
 
 
Figure 24: CD8+ T cell priming in skin of CD11c-Rac-/- and Lang-Rac-/- mice, compared to Rac1N17 
mice  
Mice received 1x106 CFSE-labeled OT-I T cells via i.v. injection. On the next day, 5 µg of pure OVA-coated 
beads were injected i.d. on the flank and 15 µl of acetone were applied on the site of immunization. Five days 
later, inguinal and axillary LNs were harvested and stained to identify OT-I cells (CD90.1+ CD8+, upper 
panels, red gate); proliferation was assessed by CFSE dilution (lower panels). Statistics represent absolute 
numbers of OT-I T cells and proportions of divided OT-I cells. Data are (Figure legend continues) 
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representative of 3 independent experiments; groups were compared by unpaired t test: not significant p>0.05; 
* 0.01>p>0.05; ** 0.001>p>0.01. Tg: transgenic Rac1N17; KO: Knockout Rac1-/-. 
 
Next, we investigated the CD4+ T cell priming in these mice. CFSE labeled OT-II 
cells were injected i.v. into mice. One day later, the same immunization procedure as 
explained above was followed. T cell response was assessed five days later.  
In no type of mouse, we could detect defects in CD4+ T cells responses (Figure 25). 
For Lang-Rac1-/- mice, this means that LCs do not influence CD4+ T cells response to 
intradermal particulate antigen. For CD11c-Rac1-/- and Rac1N17 mice, this indicates that 
migrating LCs and Langerin+ dDCs as well as sdLN resident CD8+ DCs are not involved in 
the development of a CD4+ T cell response to intradermal immunization. 
 
 
Figure 25: CD4+ T cell priming in skin of CD11c-Rac-/- and Lang-Rac-/- mice, compared to Rac1N17 
mice 
Mice received 2x106 CFSE-labeled OT-II T cells via i.v. injection. On the next day, 5 µg of pure OVA-coated 
beads were injected i.d. on the flank and 15 µl of acetone were applied on the site of immunization. Five days 
later, inguinal and axillary LNs were harvested and stained to identify OT-II cells (CD90.1+ CD4+, upper 
panels, red gate); proliferation was assessed by CFSE dilution (lower panels). Statistics represent absolute 
numbers of OT-II T cells and proportions of divided OT-II cells. Data are representative of 3 independent 
experiments; groups were compared by unpaired t test: not significant p>0.05. Tg: transgenic Rac1N17; KO: 
Knockout Rac1-/-. 
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In brief, the homeostasis and the steady state migration of LCs but not of Langerin+ 
dDCs requires Rac1 expression. Rac1 is also important for the migration under 
inflammatory conditions of both, LCs and Langerin+ dDCs. In our settings, T cell responses 
to intradermal immunization appeared independent of LCs and Langerin+ dDCs. The 
expression of Rac1N17 and the absence of Rac1 in CD11c+ cells result in different 
phenotypes. Similarly, different results are obtained when different promotors are used to 
study the effect of Rac1 deletion in Langerin+ cells. 
 
V.3 ROLE OF Rac1, Cdc42 AND RhoA IN SPLEEN DC FUNCTIONS 
V.3.1 Efficiency of the different knock-out strains 
 
As explained before, the use of a dominant negative mutant may not be completely 
specific. For this reason, we decided to test which protein functions were actually inhibited 
in Rac1N17 spleen DCs. To achieve this, we compared the phenotype of Rac1N17 spleen 
DCs with the phenotype of spleen DCs deficient for Rac1, Cdc42 or RhoA (Rac1-/-, Cdc42-/- 
and RhoA-/-). 
We first verified that the KOs were complete. Western blot analysis of spleen 
CD11c+ cells from Rac1-/-, RhoA-/- and Cdc42-/- mice confirm the absence of Rac1 (Figure 
26), RhoA (data from Nancy Luckashenak) and Cdc42 (Luckashenak et al., 2013), 
respectively. 
 
 
Figure 26: Expression of total Cdc42, RhoA and Rac1 proteins in the respective KO mice 
CD11c+ cells were isolated from spleen and lysed. Protein lysates were blotted and Rac1 quantity was 
measured compared to actin. Rac1 data are representative of 3 independent experiments. Western blots of 
Cdc42-/- and RhoA-/- spleen CD11c+ cells were obtained from Nancy Luckashenak (Cdc42-/- data are available 
in (Luckashenak et al., 2013)). Groups were compared by unpaired t test: not significant p>0.05; * 
0.01>p>0.05; ** 0.001>p>0.01; *** p<0.001. 
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V.3.2 Spleen CD8+ DC population 
 
Next, we investigated whether the KO mice have decreased CD8+ spleen DCs, 
similarly to what was published for Rac1N17 mice (Kerksiek et al., 2005). It was indeed the 
case for RhoA-/- and Rac1-/- mice but not for Cdc42-/- mice (Figure 27), reflecting a role of 
Rac1 and RhoA in the homeostasis of CD8+ spleen DCs. 
 
 
Figure 27: CD8+ DCs in spleens of the three KO mice and Rac1N17 mice 
Spleens were isolated, enzymatically digested and further stained for CD11c, MHC-II, F4/80 and CD8. The 
percentages indicated on the graphs and statistics represent the proportions of CD8+ DCs in the DC 
population. Data are representative of 3 independent experiments; groups were compared by unpaired t test: 
not significant p>0.05; * 0.01>p>0.05; ** 0.001>p>0.01; *** p<0.001. Tg: transgenic Rac1N17; KO: 
Knockout. 
 
V.3.3 Uptake of apoptotic material 
 
The uptake of apoptotic material by spleen CD8+ DCs was reduced in Rac1N17 
mice (Kerksiek et al., 2005). It was measured by the in vivo uptake of CFSE-labeled B cells 
obtained from BALB/cJ mice, which results in MHC-I mismatch leading to opsonization 
and cell death. We repeated this experiment with the three KO mice. As expected, almost 
no uptake was detected for CD8- DCs (Figure 28). However, the uptake by CD8+ DCs was 
dramatically reduced in the three KO strains, demonstrating a major role of Cdc42, RhoA 
and Rac1 in the uptake of apoptotic material by CD8+ spleen DCs. 
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Figure 28: In vivo uptake of apoptotic material in the three KO mice 
The three KO mice on C57BL/6 background received 107 CFSE-labeled B cells from BALB/cJ mice via i.v. 
injection. Spleens were harvested 14 hours later, enzymatically digested and stained for CD11c, MHC-II, 
F4/80 and CD8. The percentages indicated on the graphs and statistics represent the proportions of CFSE+ 
CD8+ DCs in the CD8+ DC population. Rac1N17 dot plots were shown for comparison here again and taken 
from (Kerksiek et al., 2005). Data are representative of 3 independent experiments; groups were compared by 
unpaired t test: not significant p>0.05; * 0.01>p>0.05; ** 0.001>p>0.01; *** p<0.001. Tg: transgenic 
Rac1N17; KO: Knockout. 
 
V.3.4 Uptake of soluble protein 
 
Previously, the in vivo uptake of OVA by Rac1N17 CD8+ DCs was shown to be 
impaired (Kerksiek et al., 2005). The CD8+ DC population being reduced in two of the 
three KO mice, we decided to test the OVA-uptake capacity of these cells in vitro. We 
isolated the spleen CD8+ DCs and incubated them with OVA-AF647 for 40 minutes. There 
was a significant decrease in the amount of OVA-AF647 taken up by the three KO and 
Rac1N17 CD8+ DCs (around 50 % OVA+ cells) as compared to control cells (around 70 % 
OVA+ cells), indicating the importance of Cdc42, RhoA and Rac1 for the uptake of OVA 
(Figure 29). 
 
 
Figure 29: In vitro uptake of soluble Ovalbumin by CD8+ DCs 
Spleens were isolated, enzymatically digested and CD8+ DCs were purified. Cells were incubated for 40 min 
at a concentration of 6x106 cells/ml with 5.µg/ml of pH insensitive OVA-AF647. (Figure legend continues) 
 58 
Cells were then intensively washed and stained for CD11c, MHC-II, F4/80 and CD8. The percentages 
indicated on the graphs and statistics represent the proportions of OVA+ CD8+ DCs in the CD8+ DC 
population. Data are representative of 2 independent experiments; groups were compared by unpaired t test: 
not significant p>0.05; * 0.01>p>0.05; ** 0.001>p>0.01. Tg: transgenic Rac1N17; KO: Knockout. 
 
V.3.5 CD8+ T cell response to soluble protein 
 
Rac1N17 spleen DCs have a cross-presentation defect in vivo (Kerksiek et al., 
2005). To find out to which extent this phenotype was due to the absence of Rac1 activity in 
CD8+ DCs, we tested the ability of the different KO spleen CD8+ DCs to induce CD8+ T 
cell proliferation in vitro. CD8+ DCs were isolated, incubated with OVA for 40 minutes, 
washed intensively and co-cultivated with CFSE-labeled OT-I cells. Three days later, T cell 
proliferation was assessed by measuring CFSE dilution. As shown in Figure 30, the CD8+ 
T cell responses induced by Cdc42-/-, RhoA-/- and Rac1N17 CD8+ DCs were reduced as 
compared to the proliferation induced by control CD8+ DCs. We concluded that Cdc42 and 
RhoA play a role in the induction of CD8+ T cell responses. In our settings, Rac1-/- CD8+ 
DCs induced a CD8+ T cell proliferation similar to the one induced by control cells. This 
result contrasts with what we observed for Rac1N17 CD8+ DCs, demonstrating that the 
phenotype obtained in Rac1N17 mice regarding T cell priming was not Rac1-specific. 
 
 
Figure 30: In vitro CD8+ T cell response to Ovalbumin 
Spleens were isolated, enzymatically digested and CD8+ DCs were purified. Cells were incubated with OVA-
AF647 for 40 min. Cells were then intensively washed and stained to know the amount of CD8+ DCs in each 
sample. Then CD8+ DCs were co-cultivated with CFSE-labeled OT-I cells at a 1:10 DC to T cell ratio for 3 
days. The overlays represent OT-I cell proliferation. OT-I cells were identified as CD8+ CD90.1+. Filled line: 
control; dotted line: KO or Tg; gray filled histogram: no antigen control. Statistics represent the proportions of 
divided OT-I cells. Data are representative of 2 independent experiments; groups were compared by unpaired t 
test: not significant p>0.05; * 0.01>p>0.05; ** 0.001>p>0.01. Tg: transgenic Rac1N17; KO: Knockout. 
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V.3.6 CD4+ T cell response to soluble protein 
 
Next, we investigated the ability of spleen CD8+ DCs to prime CD4+ T cells. We 
used the same protocol as described for the CD8+ T cell priming, expect that we used OT-II 
cells. The CD4+ T cell responses induced by Cdc42-/- and RhoA-/- CD8+ DCs were 
dramatically reduced compared to controls (Figure 31). In our settings, Rac1-/- and control 
CD8+ DCs induced a similar CD4+ T cell proliferation, whereas Rac1N17 CD8+ DCs 
generated a CD4+ T cell response that was decreased compared to control. 
 
 
Figure 31: In vitro CD4+ T cell response to Ovalbumin 
Spleens were isolated, enzymatically digested and CD8+ DCs were purified. Cells were incubated with OVA-
AF647 for 40 min. Cells were then intensively washed and stained to know the amount of CD8+ DCs in each 
sample. Then CD8+ DCs were co-cultivated with CFSE-labeled OT-II cells at a 1:10 DC to T cell ratio for 4 
days. The overlays represent OT-II cell proliferation. OT-II cells were identified as CD4+ CD90.1+. Filled line: 
control; dotted line: KO or Tg; gray filled histogram: no antigen control. Statistics represent the proportions of 
divided OT-II cells. Data are representative of 2 independent experiments; groups were compared by unpaired 
t test: not significant p>0.05; * 0.01>p>0.05; ** 0.001>p>0.01. Tg: transgenic Rac1N17; KO: Knockout. 
 
In brief, we could demonstrate that Rac1 and RhoA but not Cdc42 Rho-GTPase 
functions are required for CD8+ DCs homeostasis. We could show the involvement of 
Cdc42, RhoA and Rac1 in uptake, as well as the importance of Cdc42 and RhoA for MHC-I 
and MHC-II presentation of antigen by spleen CD8+ DCs. However, in our settings, Rac1 
was not involved in T cell responses induced by spleen CD8+ DCs. Moreover, Rac1N17 
and Rac1-/- DCs have a similar phenotype in term of antigen uptake, but they behaved 
differently in term of T cell priming, indicating that the phenotype obtained in Rac1N17 
mice was not Rac1-specific. 
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VI DISCUSSION 
VI.1 THE ROLE OF Rac1 IN LCs 
VI.1.1 General phenotype of Rac1N17 LCs 
 
Spleen DCs from Rac1N17 mice have an uptake defect and are not able to cross-
present antigen properly (Kerksiek et al., 2005; Neuenhahn et al., 2006; Luckashenak et al., 
2008; Nopora et al., 2012). However, it has been published that Rac1 has different roles in 
different cell types. As the DC population is composed of different subsets with specialized 
functions, we wanted to know if Rac1 is required for similar functions in different DC 
subsets, and decided to investigate the functional changes in Rac1N17 LCs. 
In contrast to CD8+ spleen DCs (Kerksiek et al., 2005), Rac1N17 transgene has no 
effect on LC homeostasis (Figure 10). In our settings, we could not detect any defect in 
either uptake or cross-presentation of soluble antigen by Rac1N17 LCs (Figure 12), which 
was unexpected regarding our knowledge on spleen DCs from the same mouse model. 
Compared to WT mice, we found fewer LCs in the dermis and the sdLNs of the 
Rac1N17 mice, which reveals a migratory defect of LCs at the steady state (Figure 10 and 
Figure 11). Both in vitro and in vivo migration assays under inflammatory conditions 
revealed a severe impairment of the migratory capacity of Rac1N17 LCs (Figure 13). As 
Rac1N17 LCs are able to mature, this result cannot be due to a disability of the LCs to sense 
inflammation. This was an unexpected finding, as Rac1N17 spleen DCs do not have any 
migratory defect (Kerksiek et al., 2005). It is possible that Rac1 is required for the 
mechanisms involved in the migration of LCs from epidermis to sdLNs, but not for the 
processes used by spleen DCs to travel from the red pulp to the white pulp.  
 
VI.1.2 The molecular machinery required to exit the epidermis 
 
Given the normal homeostasis of Rac1N17 LCs in the epidermis and their reduced 
frequency in the dermis (Figure 10), we were wondering if LCs could exit the epidermis. 
Therefore, we performed an in vitro migration assay from the epidermis. Here, Rac1N17 
LCs leave the epidermis in comparable amounts as WT LCs (Figure 14). This leads us to 
two hypotheses. First, the molecules required for LC migration are not normally regulated. 
Second, Rac1N17 LCs do not reorganize their cytoskeleton properly to cross the DEBM. 
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LCs need different surface molecules to exit the epidermis and to pass through the 
DEBM. The chemokine receptors CCR7 and CXCR4 were normally up-regulated, as well 
as the adhesion molecule CD44 (Figure 15.A). CCR5, which controls DC retention in the 
skin, was properly down-regulated (Figure 15.A). However, we could not detect α6-
integrin up-regulation even on control LCs (Figure 15.A), in contrast to previous 
publications on human epidermal cells (Ioffreda et al., 1993). As we are working with 
murine LCs, a species difference may explain the discrepancy. In 2006, Hamakawa and 
colleagues showed that α6-integrin level does not change upon maturation on the LC 
surface, with the same kind of isolation protocol we are using (Hamakawa et al., 2006). 
However, they have stopped their investigation after 48 hours of stimulation and have 
cultured the cells in medium and serum only, without inflammatory signals. We also did not 
detect E-cadherin down-regulation on control LCs (Figure 15.A). However, a clear down-
regulation of E-cadherin is mainly described in human LCs in case of viral infection 
(papillomavirus) and during histiocytosis or allergic contact dermatitis. Only few other 
groups have published E-cadherin down-regulation on murine LCs upon activation, but 
using stimuli different from those we used (Schwarzenberger and Udey, 1996; Jakob and 
Udey, 1998; Puttur et al., 2010). Rac1 controls the internalization of CXCR4 (Bartolome et 
al., 2004; Freret et al., 2011; Ghosh et al., 2012; Zoughlami et al., 2012). Therefore, it was 
surprising to find CXCR4 normally regulated in Rac1N17 LCs (Figure 15.A). It is possible 
that even if the Rac1N17 transgene is expressed in Rac1N17 LCs, there is still enough 
endogenous Rac1 activity remaining to mediate this phenotype. 
Furthermore, we examined the production of TGF-β and IL1-β by LCs (Figure 
15.B). As expected, the inflammation-induced IL1-β mRNA was increasing over time, but 
to the same extent in both Rac1N17 and WT LCs. In 2007, Kaplan and colleagues have 
shown that the presence of TGF-β retains LCs in the epidermis (Kaplan et al., 2007). 
However, it is not known whether it needs to be decreased to allow LC migration. As TGF-
β mRNA level was found unchanged in epidermal cells upon maturation, we conclude that 
the absence of TGF-β is sufficient but not necessary to induce LC emigration. 
Rac1 inhibition is known to lead to decreased MMP-9 production, at least in 
macrophages (Skokos et al., 2011). As keratinocytes produce MMP-9 and given the small 
number of LCs in the epidermis, it would have required a high amount of mice to get 
enough LCs to measure MMP-9 concentration. Therefore, we used in vitro generated 
BMLCs to investigate the global MMP-9 production. This production was not different 
between Rac1N17 and WT LCs (Figure 15.C). It is possible that the amount of active 
MMP-9 is different, even if Rac1N17 LCs normally generate the global MMP-9 pool. 
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MMP-2 and MT1-MMP (alias MMP-14) are also able to degrade the extracellular matrix in 
the skin (Noirey et al., 2002; Seiki, 2002). It would be interesting to investigate the 
production of active MMP-9, MMP-2 and MT1-MMP by Rac1N17 LCs. 
Furthermore, we used red fluorescence protein reporter Rac1N17 mice to investigate 
the migratory behaviour of LCs and their polarization on different DEBM components by 
two photons microscopy. However, this was not successful in our hands so far (data not 
shown). Another possibility would be to image the Rac1N17 LC cytoskeleton while the 
cells pass through the pores of the membrane of a Boyden chamber. 
All together, it seems that the migratory defect of Rac1N17 LCs is not due to the 
differential regulation of any of the molecules we have tested, and we have so far no data 
about how the cytoskeleton is reorganized in Rac1N17 LCs during the exit of the epidermis. 
 
VI.1.3 The role of LCs in T cell priming 
 
As Rac1N17 LCs have a migratory defect and therefore do not arrive properly in the 
sdLNs, Rac1N17 mice are an excellent tool to study the functions of LCs in vivo. LCs are 
the only radioresistant hematopoietic cells in the skin and the sdLNs. We exploited this 
property to generate bone marrow chimeras to address the roles of LCs in skin T cell 
responses (Figure 17 and Figure 18). To prevent soluble protein to migrate passively 
through the lymph to the sdLNs, we immunized the mice with antigen-coated beads. The 
beads were small enough to be taken up by DCs (Reis e Sousa et al., 1993; Champion et al., 
2008), but remained too big to migrate to the sdLN T cell zone (Gretz et al., 2000). 
In the Rac1N17Rac1N17 chimeras, the priming of CD8+ T cells was impaired 
compared to Rac1N17WT control mice (Figure 17.A), meaning that functional LCs 
contribute to the CD8+ T cell response induced by Rac1N17 DCs. However, even if there 
was a tendency to a decreased CD8+ T cell response in the WTRac1N17 mice compared 
to the WTWT mice, it was not significant (Figure 17.C). It is possible that in the presence 
of functional dDCs, the fewer numbers of Rac1N17 LCs arriving in the sdLNs do not have 
enough impact on the CD8+ T cell response to be detected in our settings. We haven’t found 
any contribution of LCs in the CD4+ T cell proliferation or differentiation (Figure 18). 
This study was the first to investigate the role of LCs upon intradermal 
immunization with particulate antigen. In 2011, mice with MHC-II KO LCs were 
immunized subcutaneously with peptide in complete Freund adjuvant (Shklovskaya et al., 
2011). This group did not find any influence of LCs on CD4+ T cell priming, which is 
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consistent with our findings. However, they have shown that these normally primed T cells 
could not form a memory pool, highlighting a regulatory role for LCs. Another group has 
performed gene gun immunization in mice expressing the diphtheria toxin receptor under 
the control of the murine Langerin promotor (Nagao et al., 2009). According to the antibody 
production detected two and four weeks later, they concluded that LCs promote Th2 
responses. However, when studying IFN-γ production by CD4+ T cells at the same time 
points, they could not see any effect of LCs, similarly to what we found (Figure 18.B and 
Figure 18.D). It would be interesting to further investigate the role of LCs for the 
generation of T cell memory and antibody production in the context of intradermal 
immunization with particulate antigen. 
The implication of LCs in immune responses is tightly linked to the nature of the 
antigen and to the available inflammatory signals. In case of fungi, LCs bias the response to 
a Th17 phenotype (Igyarto et al., 2011). In GVHD, they seem not to play a role (Li et al., 
2011). LCs negatively control the response to self antigen, to skin graft and to leishmaniasis 
among others (Romani et al., 2012). In the case of particulate dermal antigen, we showed 
that LCs contribute to CD8+ T cell responses without affecting the CD4+ T cell priming. 
 
VI.2 DIFFERENT MOUSE MODELS TO INVESTIGATE THE ROLE 
OF Rac1 IN SKIN DCs 
VI.2.1 Absence of Rac1 versus blockade of Rac1 GEF 
 
The dominant negative Rac1N17 protein blocks Rac1-GEFs, preventing the 
activation of Rac1 and of other Rho-GTPases that require the same GEFs (Figure 7). To 
dissect which part of the transgenic Rac1N17 LC phenotype was due to the inhibition of 
pathways controlled by Rac1, we compared the phenotype of transgenic LCs to the 
phenotype of Rac1-KO LCs from CD11c-Rac1-/- mice. 
The first discrepancy between both models was the frequency of LCs in the steady 
state epidermis (Figure 19). We found the same proportion of LCs in Rac1N17 and WT 
epidermis, whereas CD11c-Rac-/- epidermis has decreased amounts of LCs compared to its 
control. This shows that Rac1 pathways regulate LC homeostasis. The amounts of 
Langerin+ dDCs in Rac1N17 and CD11c-Rac1-/- dermis were comparable to controls 
(Figure 20), indicating that Rac1 is not required for Langerin+ dDCs homeostasis. 
The migratory phenotype however, was similar in both mice: decreased LCs in the 
steady state dermis and sdLNs (Figure 20 and Figure 21) as well as decreased migratory 
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capacity of LCs both in vitro and in vivo (Figure 22 and Figure 23); migratory defect of 
Langerin+ dDCs both in vitro and in vivo (Figure 22 and Figure 23). Therefore, pathways 
controlled by Rac1 control LC and Langerin+ dDC migration. 
Finally, we investigated the capacity of these mice to induce T cell responses to 
dermal antigen. Both mouse strains showed no defect in CD4+ T cell priming (Figure 25), 
meaning that Rac1 is not necessary for the CD4+ T cell response to skin antigen. However, 
for CD8+ T cell priming we get a second discrepancy: Rac1N17 mice but not CD11c-Rac1-/- 
mice had a reduced CD8+ T cell proliferation after intradermal immunization (Figure 24). 
Both mice have the same migratory defect for skin DCs. However, their spleen DCs have 
distinct T cell priming ability. In the third part of this study, we showed that Rac1N17 but 
not CD11c-Rac-/- spleen CD8+ DCs have an impaired cross-presentation capacity (Figure 
30). The LN resident CD8+ DCs are the counterparts of the spleen CD8+ DCs and therefore 
display the same phenotype. These facts can explain the impaired cross-presentation 
capacity of Rac1N17 mice to skin immunization, compared to CD11c-Rac-/- mice. Another 
explanation could be that Rac1N17 dDCs also have a T cell priming defect but not the 
CD11c-Rac-/- dDCs. Addressing the T cell priming capacity of Rac1N17 and CD11c-Rac-/- 
dDCs would be interesting. 
All together, we showed that Rac1 is required for LC homeostasis and for the 
migration of LCs and Langerin+ dDCs. Regarding T cell priming, Rac1 expression is not 
required for CD4+ or CD8+ T cell proliferation. The comparison of the KO model with the 
DN model revealed that the phenotypes can be different, highlighting the advantages to 
work with a specific deletion of the protein of interest. 
 
VI.2.2 CD11c versus Langerin promotor 
 
To examine the role of Rac1 in LCs and Langerin+ DCs more closely, we used 
mouse-Lang-Rac1-/- mice, which lacks Rac1 protein in LCs and CD103+ Langerin+ dDCs.  
We expected the same phenotype as in CD11c-Rac-/- mice. Indeed, we found the 
same decreased amounts of LC in epidermis, dermis and sdLNs, as well as the same normal 
proportion of Langerin+ dDCs in dermis and sdLNs (Figure 19, Figure 20 and Figure 21).  
Similar to CD11c-Rac-/- LCs, the migratory defect of Lang-Rac1-/- LCs was present 
in both mice in vitro and in vivo (Figure 22 and Figure 23). However, even if Lang-Rac1-/- 
Langerin+ dDCs showed reduced capacity to migrate in vitro, they were able to migrate in 
vivo. In the in vivo assay, the skin is exposed to inflammation, whereas in the in vitro assay 
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the cells are exposed only to chemokine signal. It is possible that the inflammatory signals 
produced in vivo overcome the chemotaxis defect of Lang-Rac1-/- Langerin+ dDCs. 
The use of the Langerin promotor to control Rac1 deletion in Langerin+ dDCs did 
not lead to a migration defect in vivo, in contrast to what we observed for CD11c-Rac-/- 
Langerin+ dDCs. Whereas LCs are long lived cells and Langerin remains expressed long 
enough to get a complete deletion of Rac1 in these cells, the life span of Langerin+ dDCs 
and the moment they begin to express Langerin remain unknown. The life span of dermal 
DCs is about 10 and 13 days, (Kamath et al., 2002; Iijima et al., 2007), but the particular 
case of Langerin+ dDCs was never investigated. Whereas CD11c is already expressed on 
DC precursors (Naik et al., 2006), the moment Langerin begins to be expressed is not 
known. A late expression of Langerin would lead to a late disappearance of Rac1 protein in 
Lang-Rac1-/- Langerin+ dDCs. In this case, by the time Lang-Rac1-/- Langerin+ dDCs 
migrate, remaining Rac1 protein would still not be completely degraded, resulting in the 
absence of phenotype. Moreover, in almost all the different stainings we showed, the 
Langerin+ dDCs had a lower expression of Langerin compared to LCs. Therefore, it is 
possible that the KO of Rac1 under the control of the Langerin promotor is less complete in 
Langerin+ dDCs than in LCs. Because there are very few LCs and Langerin+ dDCs in 
epidermis and dermis respectively, and because western blot and mRNA quantification 
require a significant amount of cells, we did not investigate whether Rac1 was absent in 
Lang-Rac1-/- and CD11c-Rac-/- LCs and Langerin+ dDCs. The previous hypotheses could 
explain the difference observed between Lang-Rac1-/- and CD11c-Rac-/- Langerin+ dDCs.  
The priming of CD4+ and CD8+ T cells in Lang-Rac1-/- mice immunized 
intradermally with particulate antigen was as strong as the priming in control mice (Figure 
25 and Figure 24). These mice only have a defect in the migration capacity of LCs, exactly 
as the bone marrow chimeras generated in the first part of this study. Therefore, obtaining 
the same results in Lang-Rac1-/- mice as in the WTRac1N17 chimeras (Figure 17.C and 
Figure 18.C) was expected. 
 
In brief, we showed that Rac1 controls LCs homeostasis as well as LC and 
Langerin+ dDC migration, but not CD8+ or CD4+ T cell responses to dermal antigen. The 
blockade of Rac1 GEFs in all the DCs (Rac1N17 mice) but not Rac1 absence (CD11c-
Rac1-/- mice) influences the CD8+ T cell priming, whereas none of them play a role in CD4+ 
T cell response. Consequently, the use of a DN protein is never as specific as the use of a 
KO to investigate the role of a particular protein. The additional defects observed in the 
Rac1N17 mouse are possibly caused by the inhibition of other Rho-GTPases such as Cdc42 
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or RhoA. Finally, the Langerin promotor may not be the most appropriate promotor to 
investigate the role of a protein in Langerin+ DCs. 
 
VI.3 ROLE OF Cdc42, RhoA AND Rac1 IN SPLEEN DC FUNCTIONS 
VI.3.1 Cdc42, RhoA and Rac1 in spleen DC homeostasis 
 
We compared spleen DCs specifically depleted of Rac1, Cdc42 or RhoA with 
Rac1N17 spleen DCs, to investigate which Rho-GTPase functions are actually inhibited in 
Rac1N17 spleen DCs. 
In Rac1N17 mice, there is a decrease in CD8+ spleen DC numbers (Kerksiek et al., 
2005). A similar reduction could be found in CD11c-Rac1-/- and CD11c-RhoA-/- but not in 
CD11c-Cdc42-/- mice (Figure 27). We conclude that in contrast to Cdc42, Rac1 and RhoA 
are involved in the homeostasis of CD8+ DCs.  
 
VI.3.2 Roles of Cdc42, RhoA and Rac1 in the control of endocytosis by 
spleen CD8+ DCs 
 
Next, we have investigated the endocytic capacities of spleen CD8+ DCs from the 
three KO strains.  
We found that the three Rho-GTPases were indispensable to take up dying cells, as 
this ability was impaired in every mouse strain (Figure 28). However, this impairment was 
less pronounced in the CD11c-Rac1-/- than in the Rac1N17 mice, maybe reflecting the 
combined block of several Rho-GTPase pathways in the Rac1N17 spleen DCs. Except for 
the Rac1 in vivo data from Kerksiek and colleagues in 2005, nothing is known about the 
involvement of these different Rho-GTPases in the uptake of apoptotic cells by DCs. In the 
literature, there are only in vitro macrophages data available, performed with DN or CA 
mutants, showing that Rac1 and Cdc42 are required for the uptake of opsonized cells 
(Hoppe and Swanson, 2004; Nakaya et al., 2006), whereas RhoA negatively regulates the 
uptake of apoptotic cells (Leverrier and Ridley, 2001; Nakaya et al., 2006). The cell type 
difference and the use of DN and CA mutants could explain the discrepancy in RhoA 
requirement.  
Next, we tested whether Rac1, Cdc42 and RhoA were also required for the uptake of 
soluble protein by spleen CD8+ DCs such as OVA, our model antigen. Cdc42-/-, Rac1-/- and 
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RhoA-/- CD8+ DCs have a reduced uptake capacity compared to the control cells (Figure 
29). Even if from previous studies with DN mutants (West et al., 2000; Shurin et al., 2005; 
Tourkova et al., 2007), it was expected for Rac1-/- and Cdc42-/- cells, this finding was 
surprising for RhoA-/- DCs. It was assessed once by drug treatment that RhoA is not 
required for receptor-mediated uptake of FITC-dextran by DCs derived from splenocytes 
cultivated for 14 days (West et al., 2000). As these splenocytes were cultivated in the 
presence of GM-SCF and TGF-β, they do not resemble the CD8+ spleen DCs. 
Taken together, Rac1, Cdc42 and RhoA proteins are required for the uptake of 
apoptotic cells and soluble OVA by spleen DCs.  
 
VI.3.3 Control of T cell priming by Cdc42-/-, RhoA-/- and Rac1-/- 
spleen CD8+ DCs 
 
In the spleen, CD8+ DCs can present antigens to both CD4+ and CD8+ T cells but 
they are specialized in cross-presentation. It was published that Rac1N17 mice have a cross-
presentation defect (Kerksiek et al., 2005; Neuenhahn et al., 2006; Nopora et al., 2012) but 
normal CD4+ T cell priming capacity (Luckashenak et al., 2008). 
Addressing these functions in the KO mice revealed that Cdc42-/- and RhoA-/- spleen 
CD8+ DCs induced reduced in vitro proliferation of both CD8+ and CD4+ T cells compared 
to control mice (Figure 30 and Figure 31). This demonstrates the role of Cdc42 and RhoA 
in CD8+ and CD4+ T cell priming. Shurin and colleagues have shown that BMDCs 
transfected with RhoA or Cdc42 CA mutants both induced an increased CD4+ T cell 
response to OVA (Shurin et al., 2005), which is in accordance with our results. Cdc42 was 
shown to be involved in the polarization of MTOC at the immunological synapse with 
CD8+ T cells (Pulecio et al., 2010). This polarization is essential for IL12 production at the 
immunological synapse as well as for the proper activation of CD8+ T cells. Therefore, 
similar to us, they found a decreased CD8+ T cell response in the absence of Cdc42. Our 
study with Cdc42-/- and RhoA-/- spleen CD8+ DCs also provides a direct proof of the role of 
Cdc42 and RhoA in CD4+ T cell priming and cross-presentation.  
Rac1-/- spleen CD8+ DCs induced the same in vitro proliferation of CD4+ and CD8+ 
T cells as control cells (Figure 30 and Figure 31), suggesting that Rac1 is neither involved 
in cross-presentation nor CD4+ T cell priming. To the contrary, Rac1N17 CD8+ DCs 
induced reduced CD4+ and CD8+ T cell proliferation (Figure 30 and Figure 31). The two 
studies investigating the role of Rac1 in cross-presentation used a dominant negative form 
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of Rac1 (Jaksits et al., 2004; Kerksiek et al., 2005). Therefore, there is no direct data in the 
literature to discuss the differences between the cross-presentation capacities of Rac1-/- and 
Rac1N17 CD8+ DCs. Benvenuti and colleagues have demonstrated that a single KO of 
Rac1 or Rac2 was insufficient to get a decreased CD4+ T cell priming in response to peptide 
presentation (Benvenuti et al., 2004). Solely the cumulative KO of both Rac1 and Rac2 was 
resulting in reduced CD4+ T cell response. It is most likely that the GEFs activating Rac1 
are the same as the ones activating Rac2, which would lead to a cumulative inhibition of 
endogenous Rac1 and Rac2 activities in Rac1N17 cells. It could explain the discrepancy 
between the CD4+ T cell priming and the cross-presentation capacities of Rac1-/- and 
Rac1N17 CD8+ DCs. It was intriguing that Rac1-/- CD8+ DCs perform reduced antigen 
uptake but normal T cell priming. It is possible that peptide generation for cross-
presentation and MHC-II presentation is better in absence of Rac1. One should also 
investigate whether peptide presentation itself is increased in Rac1-/- CD8+ DCs. 
In brief, spleen CD8+ DC homeostasis is controlled by RhoA and Rac1; Cdc42, 
RhoA and Rac1 are involved in the uptake of apoptotic cells and soluble protein; and RhoA 
and Cdc42 are essential for both CD8+ and CD4+ T cell priming whereas Rac1 is not. 
Finally, the phenotype of Rac1N17 mice does not reflect Rac1 inhibition only. 
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VII CONCLUSION 
 
This project investigates the role of Rho-GTPases in LC and spleen DC functions by 
the use of different mouse models. 
We first hypothesized that the Rho-GTPase Rac1 could be required for different 
functions in different DC subsets. Our investigation of Rac1N17 LC functions confirms this 
hypothesis. Rac1N17 LCs mature, take up antigen and present it to CD8+ and CD4+ T cells 
normally. However, their migratory capacity is impaired. The examined molecules required 
for migration were normally regulated. It is possible that this migration defect is due to a 
more general problem in the cytoskeleton coordination. Using these mice with migration 
defective LCs, we generated bone marrow chimeras to investigate the role of LCs in skin T 
cell response. It appears that LCs contribute to CD8+ T cell response to particulate dermal 
antigen, without affecting T cell differentiation. However, LCs play no role in the CD4+ T 
cell response in the same settings. 
Second, we examine skin DCs from Rac1N17, CD11c-Rac-/- and Lang-Rac1-/- mice 
to determine which mouse model would be the most appropriate for the study of Rac1 
functions in LCs and Langerin+ dDCs. This study showed that Rac1 is implicated in the 
homeostasis of LCs but not of Langerin+ dDCs. LCs and Langerin+ dDCs display a 
migration defect, highlighting a crucial role of Rac1 in this process. The CD11c-Rac-/- 
mouse phenotype indicates that Rac1 is dispensable for T cell responses against dermal 
antigens, in contrast to Rac1N17 mice. The comparison of CD11c-Rac-/- to Lang-Rac1-/- 
mice revealed that the Langerin promotor might not be ideal to investigate the role of a 
protein in Langerin+ dDCs. 
Finally, we examined whether only the Rac1 pathway was inhibited in Rac1N17 
spleen DCs. To do so, we compared Rac1N17 spleen CD8+ DCs with CD11c-Rac1-/-, 
CD11c-Cdc42-/- and CD11c-RhoA-/- spleen CD8+ DCs. Rac1 and RhoA but not Cdc42 are 
required for CD8+ spleen DC homeostasis. The three Rho-GTPases control the 
phagocytosis of apoptotic cells and the uptake of soluble protein by spleen CD8+ DCs, 
which was surprising for RhoA. The resulting CD4+ and CD8+ T cell responses were 
dramatically impaired when induced by Cdc42 and RhoA spleen CD8+ DCs. For the first 
time a direct proof of RhoA involvement in T cell priming by DCs is provided. The normal 
T cell responses induced by CD11c-Rac1-/- CD8+ DCs were unexpected and argue for the 
fact that Rac1 is not required for cross-presentation and that the phenotype observed in 
Rac1N17 mice is not due to Rac1 inhibition only. 
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In brief, we provided evidences that the Rac1N17 model is not entirely specific for 
Rac1. We could show the involvement of Rac1 in LC homeostasis and migration, as well as 
its role in the uptake of apoptotic cells and soluble antigen by spleen DCs. Surprisingly 
Rac1 is not implicated in cross-presentation. We demonstrated the indispensable role of 
Cdc42 and RhoA in spleen CD8+ DCs for both antigen uptake and T cell priming. Finally, 
we showed that LCs contribute to CD8+ T cell response to dermal antigen. 
 
 
Graphical abstract 
A: The Rac1N17 model is not specific for Rac1. The dominant negative Rac1N17 protein remains bound to 
GEFs able to activate Rac1. These GEFs are Rac1-specific only or activate other Rho-GTPases such as Rac2, 
Cdc42 or RhoA. Therefore, Rac1N17 phenotype is the result of the blockade of several Rho-GTPases. B: 
Rac1 functions in Langerin+ skin DCs. Rac1 is implicated in the homeostasis of LCs but not of Langerin+ 
dDCs. The migration capacity of both LCs and Langerin+ dDCs requires Rac1 activity. C: LCs contribute to 
CD8+ T cell responses to dermal antigens. Rac1N17 DCs induce CD4+ and CD8+ T cell priming (left, purple 
cells), but the presence of functional LCs (right, green cells) leads to increased CD8+ T cell proliferation (as 
shown in bone marrow chimeras). Tg: transgenic Rac1N17; WT: control; sdLN: skin draining lymph node. D: 
The role of Rac1, Cdc42 and RhoA in spleen CD8+ DCs. Rac1 and RhoA are required for proper CD8+ DC 
homeostasis. Rac1, Cdc42 and RhoA control the uptake of both soluble protein and dying cells by spleen 
CD8+ DCs. The CD8+ and CD4+ T cell priming by spleen CD8+ DCs is dependent on Cdc42 and RhoA but 
not on Rac1. 
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